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Abstract 
Defining the Placental Barrier to Toxoplasma gondii Infection 
 
Stephanie Elaine Ander, PhD 
 
University of Pittsburgh, 2019 
 
 
 
 
Toxoplasma gondii is a major source of congenital disease worldwide, but the cellular and 
molecular factors associated with its vertical transmission are largely unknown. In humans, the 
placenta forms the key interface between the maternal and fetal compartments and forms the 
primary barrier that restricts the hematogenous spread of microorganisms.  This dissertation 
describes both the identification of two mechanisms of placental syncytiotrophoblast resistance to 
T. gondii infection and a preliminary understanding of the CCL22 response induced by the 
Toxoplasma dense granule protein GRA28. Collectively, these findings provide new insights into 
(1) protective role of the syncytiotrophoblast during T. gondii infection, (2) interferon-γ 
independent restriction of T. gondii growth, and (3) parasite-directed manipulation of the 
intercellular communication between the placenta and components of the maternal immune 
system. 
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1.0 Introduction 
Toxoplasma gondii is an obligate, intracellular protozoan that is believed to infect all 
warm-blooded animals, including humans. Based upon serology, it is estimated that one-third of 
the global human population has been infected, although the degree of seroprevalence varies 
widely amongst different geographical regions [1]. Most infections with Toxoplasma are 
subclinical, and while infection is considered to be life-long, the otherwise healthy individual 
experiences no health complications. However, vertical transmission of Toxoplasma during 
pregnancy can be fatal for the developing fetus. This chapter will discuss the immunology of the 
maternal-fetal interface, key aspects of Toxoplasma biology, and congenital toxoplasmosis in order 
to understand the biological barriers that the parasite must overcome to cause fetal disease as well 
as the consequences of congenital infection. 
1.1 Immune Responses at the Maternal-Fetal Interface 
Pregnancy poses an immunological challenge, as a genetically distinct (non-self) fetus 
must be supported within the pregnant female for the required gestational period. Placentation, or 
the establishment of the fetally-derived placenta, is a common strategy employed by eutherian 
mammals to protect the fetus and promote its growth. However, the substantial morphological 
differences of the placental architecture among species suggest that the process of placentation 
results from convergent evolution. Although there are considerable similarities in placental 
function across placental mammals, there are important differences that arise due to species-
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specific immunological (and other biological) constraints. This subchapter focuses on the 
immunological similarities and differences that occur at the maternal-fetal interface in the context 
of human and mouse pregnancies. Herein will be discussed how the decidua and placenta of these 
different species form key immunological barriers that sustain maternal tolerance, yet generate 
innate immune responses that prevent microbial infections. 
1.1.1  Introduction 
Placentation is a common strategy employed across eutherian mammals to protect and 
promote fetal growth. Although mice are commonly used to study the maternal-fetal interface 
within the immunological context of pregnancy, differences exist in placental architecture, 
gestational period, and mechanisms of maternal tolerance from humans. Throughout this review, 
we focus on the immunological similarities and differences during human and mouse pregnancies. 
We define the fetal and maternal components, their interactions, and mechanisms of mediating 
maternal tolerance in both species. We also examine the role of the placenta as a barrier to 
maternally-transmitted pathogens and conclude with a discussion on the strengths and weaknesses 
of commonly used models of the human placenta. 
1.1.2  The Maternal-Fetal Interface in Humans and Mice 
The maternal-fetal interface is composed of the maternally-derived decidua and the fetally-
derived placenta (Figure 1). In both mice and humans, the placenta develops from the 
trophectoderm of the blastocyst. During implantation, invading trophoblasts anchor the blastocyst 
to the specialized uterine epithelium (the decidua), upon which placentation ensues. Over the 
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course of pregnancy, the placenta is the sole site for all gas, nutrient, and waste exchange between 
the fetus and mother.  
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Figure 1 Comparison of Human and Mouse Placentation 
Prior to placentation, the blastocysts of humans and mice are similar (left). However, upon implantation placental 
development progresses differently (middle and right). Following blastocyst implantation, the human 
syncytiotrophoblast layer burrows into the maternal decidua (top middle). By the third week of gestation, the definitive 
human placenta is formed and is composed of villous trees. However, at this stage of human pregnancy, the fetal-
derived placenta does not directly contact maternal blood. Extravillous trophoblasts anchor the villi to the decidua and 
are involved in the remodeling of the spiral arteries to flood the intervillous space with maternal blood towards the 
end of the first trimester of pregnancy (top right). The surface of the villi are covered by the syncytiotrophoblast layer, 
which directly contacts the maternal blood and facilitates the transport of nutrients, gases, and waste across the 
placental barrier. Underlying the syncytiotrophoblast layer are mononucleated cytotrophoblasts that can either fuse to 
replenish the syncytial layer or differentiate into extravillous trophoblasts. In contrast, mouse placental development 
and organization is different from that in humans. Upon implantation, the trophectoderm differentiates and trophoblast 
giant cells encapsulate the developing mouse embryo (bottom middle). Halfway through gestation, the definitive 
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murine placenta is fully formed and functional, where the folded villi form a labyrinth structure that becomes perfused 
with maternal blood (bottom right). The trophoblast giant cells channel maternal blood from the decidua through the 
spongiotrophoblast layer (a structure not present in the human placenta) toward the labyrinth zone. In the labyrinth 
zone, the maternal blood makes contact with the cytotrophoblasts that overlay two separate layers of 
syncytiotrophoblasts. Graphics generated by A. Kitterman/Science Immunology. 
1.1.2.1 Decidua Formation 
The placenta is embedded within the decidua, the maternal component of the maternal-
fetal interface. The decidua only exists during pregnancy and originates from the endometrial 
lining of the uterus (the endometrium). At the conclusion of pregnancy (parturition), the decidua 
is shed, to be rebuilt only upon subsequent pregnancy. However, signs of pre-decidualization can 
be observed within the non-pregnant human endometrium halfway through the luteal phase 
(around days 23-25 of the menstrual cycle) including: increased prominence of the spiral arterioles, 
differentiation of endometrial fibroblast-like cells into enlarged and granulated decidual stromal 
cells, and an influx of leukocytes [2]. It is important to note that timing is critical for pregnancy to 
occur. Implantation must take place prior to this pre-decidualization, as this thickening of the 
endometrium is not amenable for implantation. 
During decidualization there is both fetally and maternally mediated remodeling of the 
spiral arteries so that the placenta becomes bathed in maternal blood, which facilitates exchange 
of nutrients, gases, and waste. After implantation, the endothelial lining of the spiral arteries is 
eroded (as well as the local decidual stromal cells), creating a fibrinoid wall embedded with 
invasive fetal placental trophoblasts [3]. Maternal leukocytes, such as natural killer cells and 
macrophages, have been implicated in this remodeling process (see later section on maternal 
leukocytes). These concordant efforts of fetal trophoblasts and maternal leukocytes result in the 
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dilation of the spiral arteries, which decreases the force and maximizes the volume of the maternal 
blood bathing the placenta [3]. 
1.1.2.2 Placental Development 
In humans, the definitive structure of the placenta is composed of villous trees and is 
established by the third week of gestation (Figure 1 and 2). The structure of the human placenta 
is composed of both floating and anchoring villi. A single layer of contiguous multinucleated 
syncytiotrophoblasts (SYN) lines the outermost surface of the human placenta villous trees and 
acts as the major cellular barrier between the fetal compartment and maternal blood. Underlying 
the SYN layer are the undifferentiated, mononucleated cytotrophoblasts (CTBs). CTBs are 
progenitor trophoblast cells and can fuse to replenish the SYN layer or differentiate into 
mononucleated extravillous trophoblasts (EVTs), which are located at the tips of the anchoring 
villi. During the first trimester, the human placenta is hemodichorial, with two layers of 
trophoblasts separating the fetal and maternal bloodstreams (the SYN and CTBs). As the placenta 
grows, the underlying CTB layer thins and becomes dispersed; thus, the human placenta of the 
second and third trimesters is essentially hemomonochorial, with only a single layer of SYNs.  
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Figure 2 Timeline of Human and Mouse Placentation 
The human early blastocyst forms around day 4 (d4) and is marked by the development of the trophectoderm—the 
first differentiation event in mammalian development. The primitive intervillous space (IVS) forms around d8-9 from 
the coalescence of vacuoles forming within the syncytiotrophoblast (SYN) mass (creating lacunae). In between the 
lacunae are columns of SYN (trabeculae), which are invaded by cytotrophoblasts (CTB) around d12 to form nascent 
villi. Around d15, the CTB invade the decidua (a task previously performed by the SYN for implantation). By d21, 
the definitive placenta is formed. However, maternal blood does not flood the IVS until weeks 10-12. In contrast, the 
gestational period of mice lasts just 20 days. Other differences between human and mice include the development of 
the choriovitelline placenta at d8. This primitive placenta (not formed in human gestation) is composed of the 
juxtaposition of the yolk sac against the maternal tissues and blood vessels. At d11-12.5, the yolk sac placenta is 
supplanted by the chorioallantoic (definitive) placenta, and around d14.5 for the mouse, the CTB layer covering the 
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villi becomes perforated, and maternal blood can now directly contact the outermost SYN layer. Graphics generated 
by A. Kitterman/Science Immunology. 
 
The SYN facilitates the transport of nutrients, gases, and waste across the maternal-fetal 
interface. The SYN also functions as the main endocrine cell of the placenta, producing human 
chorionic gonadotropin (hCG) and progesterone, vital hormones that support pregnancy [4]. 
During the first eight weeks of gestation, the SYN secretion of hCG is required to induce 
progesterone production by the corpus luteum [5]. Afterwards, the placenta itself becomes the 
major producer of progesterone [5]. While the mouse also requires progesterone during the course 
of gestation, its placenta does not synthesize progesterone, and instead continuously throughout 
pregnancy relies upon the corpus luteum for progesterone [4].  
EVTs physically anchor the human placenta to the decidua. The invasive EVTs also are 
important for remodeling the spiral arteries in the outer third of the myometrium. In the first 
trimester, EVTs act as a plug for the spiral arteries, thus creating a hypoxic environment by 
excluding the oxygen-rich maternal blood. During the transition from the first to the second 
trimester, the EVT plug is eroded and the intervillous space (IVS) becomes flooded with maternal 
blood (Figure 2). Later during gestation, the IVS can fill with as much as 150 mL of maternal 
blood. The presence of maternal blood in direct contact with the SYN allows for efficient gas, 
nutrient, and waste exchange, which is maintained throughout the rest of pregnancy. As the direct 
contact of maternal blood with the placenta does not occur until the end of the first trimester, this 
event distinguishes the early (first trimester) and later (second and third trimesters) stages of 
pregnancy. 
In the early stage of pregnancy, the IVS is filled with a clear fluid containing uterine gland 
secretions, which are phagocytosed by the SYN and serve as a nutrient source for the developing 
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fetus [6]. Uterine glands originate from invaginations of the endometrium and are required for 
establishing pregnancy. Among their varied secretions are growth factors that regulate placental 
development, including epidermal growth factor, vascular endothelial growth factor (VEGF), 
transforming growth factor beta (TGF-β), and leukemia inhibitory factor [7].  
1.1.2.3 Decidualization and Placentation in the Mouse 
Key differences exist between mice and humans during the stages of pregnancy. In 
particular, the timeframe and establishment of the maternal-fetal interface in each species is 
distinct. Human gestation takes place over a period of 40 weeks, whereas in mice, it is 
approximately 3 weeks (Figure 2). The timing of decidua formation and placentation also varies. 
In humans, the uterus is primed for decidualization, independent of fertilization, around menstrual 
cycle day 23 when the stromal cells near the (now prominent) spiral arteries begin to differentiate 
into large predecidual cells [2]. However, in mice, spiral artery outgrowth and decidualization does 
not begin until fertilization and blastocyst attachment to the uterus, respectively [3]. Likewise, the 
placenta does not have a definitive structure in mice until the mid-point of gestation (around day 
10.5-11.5); whereas, the definitive placenta in humans forms far earlier in relative development 
(around day 21) [4]. Thus, timing is critical to experimental design and interpretation when using 
the mouse (or any other animal) to model human pregnancy. A timeline highlighting the 
differences between the human and mouse placentation and the key events that occur throughout 
pregnancy is shown in Figure 2.  
Although the hemochorial mouse placenta shares features with the human placenta, several 
differences exist that impact physiology, immunity, and development (Figure 1). Whereas the 
human placenta is structured as villous trees bathed in maternal blood (after the first trimester), the 
mouse placenta has a labyrinth structure perfused by maternal blood. In the mouse, the maternal 
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blood is directed through trophoblast giant cell-lined channels in the spongiotrophoblast layer (a 
cell type not present in the human placenta) to the chorionic plate and back through the labyrinth 
zone containing the fetal vasculature [8]. Unlike the anchoring chorionic villi of humans, the 
mouse chorionic projections are highly interconnected, presenting a maze-like structure through 
which the maternal blood must pass to leave the placenta. This labyrinth chorionic structure is 
lined by three layers of trophoblasts: two layers of SYNs overlaid with CTBs. In further contrast 
to the human placenta, the murine CTBs directly contact the maternal blood. The trophoblast giant 
cells (large polypoid cells) anchor the mouse placenta to the decidua. Unlike human EVTs, murine 
giant cells are minimally invasive and do not remodel the maternal spiral arteries. These 
differences in physiology may impact the placental barrier functionally and the types of strategies 
utilized to protect the fetus from activation of the maternal immune system, as well as impacting 
the pathways used by circulating pathogens to access the fetus.  
1.1.3  Leukocytes at the Maternal-Fetal Interface 
In addition to stromal cells, a remarkably large portion (~40%) of the decidua is composed 
of maternal leukocytes (Figure 3). In the first trimester, decidua basalis (the site of implantation 
and trophoblast invasion/remodeling), decidual natural killer cells (dNK) comprise the majority 
(~70%) of immune cells, followed by decidual macrophages (20-25%), and T cells (3-10%) [9, 
10]. Maternal leukocytes are present in the decidua throughout pregnancy, although the population 
frequencies change, with far more dNK and decidual macrophages present at earlier stages of 
pregnancy than at term [11, 12]. These maternal leukocytes are recruited by chemokine gradients 
produced by decidual stromal cells and trophoblasts [13, 14], and are typically distinct from their 
peripherally circulating counterparts in phenotype and function (discussed below). It should be 
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noted that most of our understanding of maternal leukocytes at the maternal-fetal interface has 
been determined from mouse studies and correlated to observations in human patient samples. 
Whereas the majority of the decidual leukocytes are dNKs and decidual macrophages, T cells 
subsets also have key functions. For more detailed information about leukocytes present at the 
maternal-fetal interface, the reader is referred to several excellent recent reviews [9, 10, 15].  
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Figure 3 Mechanisms of Maternal Tolerance 
The most abundant of the maternal immune cells present in the decidua are decidual natural killer cells (dNKs), which 
are recruited by various factors released from the decidual stromal cells and placental trophoblasts. The release of 
uterine IL-15 promotes dNK maturation. The mature dNK cell promotes decidual remodeling and blastocyst 
implantation through the secretion of cytokines (including IFNᵧ, VEGF, and TNFα). The release of IL-8 and CXCL10 
by dNK also promotes extravillous trophoblast (EVT) invasion. dNK cell cytotoxicity is controlled by the binding of 
HLA-G (expressed on the EVTs) to the inhibitory receptor KIR2DL4. dMØ prevent maternal intolerance by producing 
IDO, which hinders T cell activation, and phagocytosing apoptotic trophoblasts. Tregs modulate the activities of both 
antigen presenting cells and effector T cells. The syncytiotrophoblast also promotes maternal tolerance by secreting 
exosomes expressing TRAIL and FasL and by the lack of any MHC expression. Graphics generated by A. 
Kitterman/Science Immunology. 
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1.1.3.1 Decidual Natural Killer Cells 
Decidual NK cells are the largest population of maternal leukocytes that accumulate at the 
maternal-fetal interface, where they contribute to decidualization and implantation. Unlike their 
circulating counterparts, dNKs produce a vast array of growth factors, angiogenic factors, and 
cytokines [16]. Through these secretions, they help to remodel the decidua and spiral arteries, 
promote trophoblast invasion, and increase the availability of maternal blood at the implantation 
site [16–20]. In the mouse decidua, dilation of the spiral arteries is induced by dNK-secreted type 
II interferon (IFN-γ [21]. dNK production of IL-8 and CXCL10 has been implicated in promoting 
EVT migration into the placental bed [16]. An absence of dNKs in murine pregnancies is 
associated with decreased fetus viability and abnormal formation the decidual structure and spiral 
arteries at the implantation site [22, 23]. Analogously, in human patients with unexplained 
infertility, endometrial biopsies have found significantly fewer NK cells than fertile counterparts 
[24]. Interestingly, a subpopulation of dNKs that exhibit enhanced production of  IFN-γ and 
VEGFα has been identified recently as highly enriched in multigravid women [25]. These 
Pregnancy Trained dNKs (PTdNKs) are transcriptionally unique from other dNKs, with higher 
expression of genes related to NK cell activation, growth factors, and immunomodulatory proteins 
[25]. Using single-cell transcriptomics, another recent study identified three subsets of dNKs in 
the first trimester decidua, including a highly active subset of dNKs with characteristics similar to 
the previously described PTdNKs [26]. As improved placentation is seen upon subsequent 
pregnancies [27], it is interesting to speculate that this subset of dNKs may become enriched upon 
subsequent pregnancies and  boost decidua receptivity.  
The dNK cells of pregnancy are phenotypically distinct from the peripherally circulating 
NK cells, and their specific origins remain enigmatic and may differ between humans and mice 
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[9]. These cells are highly granulated and distinguished as CD56++CD16- (human) or CD122+CD3- 
(mouse) [9]. The precursors of dNK cells are speculated to include the uterine hematopoietic stem 
cells and/or differentiation of thymic or peripheral NK cells [28–30], with the final differentiation 
into mature dNK cells driven, at least in part, by uterine IL-15 production [31]. The size of the NK 
cell population in the uterus is regulated by endocrine signaling. Following the human menstrual 
cycle, there is a cyclic enrichment of NK cells in the uterus post-ovulation that is sustained by 
pregnancy. In contrast, the population of NK cells in the mouse uterus does not accumulate until 
blastocyst implantation [9]. It should be noted that in the murine model of artificial decidualization, 
placement of an inert bead in the uterus of hormone-stimulated mice can stimulate local uterine 
NK to differentiate into dNK cells [32]. However, these cells are not as functionally active as those 
derived in the presence of a conceptus [32].  
1.1.3.2 Decidual Macrophages 
Decidual macrophages are the primary antigen presenting cells (APCs) at the maternal-
fetal interface in early pregnancy [10]. Like uterine NK cells, levels of uterine macrophages rise 
and fall with the menstrual cycle and then increase upon fertilization [33, 34]. Phenotypically, 
decidual macrophages are believed to exist as regulatory/homeostatic, anti-inflammatory cells of 
an M2-like phenotype [10]. The phenotype of decidual macrophages is believed to be influenced 
by trophoblasts, which secrete macrophage colony-stimulating factor (M-CSF) and IL-10 [35]. 
Human decidual macrophages are CD163+CD206+DC-SIGN+ and predominantly express IL-10, 
CCL2, and CCL18 [36–41].  
Decidual macrophages have many functions during pregnancy. Like dNK cells, they aid in 
remodeling of the spiral arteries and trophoblast invasion [42, 43], and localize to sites of 
disruption near the spiral arteries [44]. Decidual macrophages in vitro produce VEGF and matrix 
 15 
metalloproteinase 9 (MMP9), which may promote angiogenesis and tissue remodeling [39, 45, 
46]. Decidual macrophages are proposed to perform “cleanup” functions by phagocytosing 
apoptotic trophoblasts, which prevents activation of pro-inflammatory pathways in the decidua 
[47–50]. These cells also produce indoleamine 2, 3-dioxygenase (IDO), which catabolizes 
tryptophan and hinders T cell activation [51, 52]. Decidual macrophages also may have a more 
canonical antimicrobial role in protecting the fetus against infections, as suggested by the surface 
expression of pattern recognition receptors CD163 (hemoglobin scavenger receptor), CD206 
(mannose receptor), and CD209 (DC-SIGN) [53]. 
1.1.3.3 Regulatory T cells 
The importance of regulatory T cells (Tregs) in pregnancy has become increasingly 
apparent. Observational experiments with human samples demonstrate the presence of Tregs in 
the human decidua, and cases of human infertility, recurrent spontaneous abortions, and other 
pregnancy complications have been inversely correlated with Treg frequencies or functionality 
[54–57]. In mice, fetal specific Tregs are recruited to and induced at the maternal-fetal interface 
where they confer tolerance to fetal antigens and help maintain a homeostatic environment 
conducive to fetal survival. Fetal specific Tregs are capable of persisting beyond parturition, while 
maintaining their functionality [58]. Upon subsequent pregnancy with the same paternal 
background, the expansion of these cells correlates with decreased fetal resorption [58]. 
Intriguingly, the origins of these fetal specific Tregs may be linked to the in utero exposure of non-
inherited maternal antigens (NIMA). A multigenerational mouse study found pregnancies to be 
more successful when the sire has overlapping allogenicity with the maternal grandmother [59]. 
Thus, in utero exposure to NIMA may expand a female’s Treg repertoire and explain the presence 
of maternal Tregs specific for fetal (non-self) antigen [59].  
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1.1.4  Maternal Tolerance 
Maternal tolerance, which permits a mother to carry the fetus to term despite the presence 
of foreign fetal antigen, is a poorly understood phenomenon that seems to defy some of the basic 
tenets of immunology. For a successful pregnancy, maternal tolerance must be established, and 
failure of maternal tolerance is correlated with pre-eclampsia and miscarriage [60–62]. In general, 
tolerance is mediated by the restriction and modulation of leukocytes that permeate the maternal-
fetal interface. Although there is an abundance of NK cells in the decidua, the numbers of DCs 
and effector T cells are low. As has been demonstrated in the mouse decidua, this may be due to 
the absence of local lymphatic vasculature in the endometrium [63, 64] and epigenetic silencing 
of T cell chemoattractants in decidual stromal cells [65]. As for leukocytes that do gain access to 
the maternal-fetal interface, intercellular communication between the resident decidual leukocytes, 
stromal cells, and trophoblasts can alter the functional profile of leukocytes and promote regulatory 
phenotypes. For example, first trimester human placental explants produce G-CSF, IL-10, and 
TGF-β, which are known to promote differentiation of peripherally circulating monocytes and T 
cells into M2 MØ and Tregs, respectively [35]. Apoptosis also is employed to mediate immune 
privilege. The SYN secretes exosomes expressing TRAIL and Fas ligand on their surface, which 
are capable of binding to their cognate death receptors on leukocytes to trigger apoptosis [66].  
Maternal tolerance also may occur through species-specific mechanisms. In humans, 
placental EVTs express HLA-G, a non-classical MHC molecule, for which there is no homolog in 
the mouse genome. Unlike the canonical class I MHC molecules, of which exist thousands of 
allelic variations that serve to distinguish self from non-self, there are only 16 protein variants of 
HLA-G [67]. Uniquely expressed by EVTs, HLA-G binds to dNK inhibitory receptors KIR2DL4 
[68] and LILRB [69] to protect the trophoblasts from NK-mediated cytolysis [70]. Likewise, the 
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membrane-localized regulator of complement, Crry, is an example of a rodent-specific mechanism 
which protects the mouse placenta from the deposition and activation of circulating maternal 
complement, and its expression is required for fetal survival [71]. As Crry is rodent-specific, it 
remains to be determined whether the human placenta also expresses such complement regulatory 
proteins that inhibit complement deposition and activation. Such disparities in mediating maternal 
tolerance  between mice and man may be due to differences in the degree of placental invasiveness 
and length of gestational period. Likewise, different mechanisms could have arisen independently 
to handle the same problem of maternal immune responses that antagonize fetal viability. 
1.1.5  Intrinsic Immune Responses of the Placenta 
Once the IVS fills with maternal blood, the placenta is continuously exposed to any and all 
pathogens circulating systemically in the maternal circulation. As such, the placenta possesses 
several intrinsic defenses to protect the fetus from infection (Figure 4).  
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Figure 4 Mechanisms of Placental Immune Defense 
The placenta has a number of innate immune mechanisms to protect the fetus from congenital infections of all types, 
including the expression of pattern recognition receptors (PRRs) such as toll-like receptors (TLRs), the constitutive 
expression of type III interferons (IFN-λ), and the release of antimicrobial peptides. Inoculation of placental 
trophoblasts with the parasite Toxoplasma gondii induces the secretion of chemokines, including the potent Th2 and 
Treg chemoattractant CCL22, suggesting that parasite infection alters or signals to maternal-derived immune cells. 
Furthermore, SYN expression of the neonatal Fc receptor also suggests a protective role for maternal IgG within the 
fetal compartment through the development of passive immunity. Graphics generated by A. Kitterman/Science 
Immunology. 
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1.1.5.1 Structure and Location 
The architecture of the human placenta allows it to present its strongest cellular defense, 
the SYN layer, on its outermost surface. The SYN forms a single continuous cell, and thus lacks 
cellular junctions that can be exploited by pathogens or modulated by inflammatory signals. This 
contrasts with the mouse, which is arranged with the two layers of SYN buried beneath the CTBs 
contacting the maternal bloodstream. Another physical property that confers microbial resistance 
to the SYN is the dense cytoskeletal network that creates a dense brush-border formed at the apical 
surface. This brush border provides a vast surface area for nutrient and gas exchange between the 
maternal and fetal compartments, but also protects from direct microbial invasion, in part due to 
the dense underlying actin network. For example, SYN are highly resistant to infection by Listeria 
monocytogenes [72], but become more permissive upon pharmacological disruption of the actin 
cytoskeleton [73]. In addition, SYN restrict Toxoplasma gondii entry, most likely via a unique 
plasma membrane composition not amenable to parasite attachment [74, 75]. 
1.1.5.2 Secreted Antiviral Factors 
The placenta secretes antiviral molecules that broadly function to restrict viral infections. 
The SYN layer constitutively secretes type III IFNs (IFN-λ) and vesicle-enclosed primate-specific 
placental microRNAs (C19MC, chromosome 19 microRNA cluster) that restrict viral infections 
in autocrine and paracrine manners [76, 77]. Whereas C19MC miRNAs are unique to primates, 
and it is unclear whether mice express an analogous inhibitory miRNA, the murine placenta also 
uses type III IFNs to protect against viral infections. Mid-gestation murine fetuses lacking IFN-λ 
signaling are more permissive to Zika virus (ZIKV) infection and vertical transmission [78]. 
Likewise, injection of pregnant dams with pegylated IFN-λ restricted vertical transmission of 
ZIKV [78, 79].  
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1.1.5.3 Transport of Passive Immunity 
The human placenta also can actively transport protective antibodies to the fetus via 
expression of the IgG receptors neonatal FcRn and FcɣRIII on the surface of the SYN layer. This 
transplacental passage of maternal humoral immunity in humans begins at week 16 of gestation 
and increases during the course of pregnancy, such that at term, the fetus has a greater serum 
concentration of maternally-derived IgG than the mother [80]. The murine chorionic placenta does 
not transport IgG as efficiently; instead mice acquire the bulk of maternal antibodies via FcRn 
expression on yolk sac-derived cells and after birth via suckling [81, 82].  
1.1.5.4 Intracellular Defenses 
In addition to these processes, the placenta can directly initiate innate defenses aimed at 
suppressing microbial infections and/or alerting the maternal immune system to infection. 
Placental trophoblasts recognize pathogens via toll-like receptors and RIG-I-like receptors, which 
trigger the induction of antimicrobial signaling pathways [83, 84]. Trophoblasts also exhibit high 
rates of basal autophagy, which can serve as a pan-antimicrobial strategy to restrict the replication 
of diverse intracellular pathogens [76, 85].  
1.1.6  Modeling the Maternal-Fetal Interface for Congenital Infection Studies 
Despite the formidable barrier presented by the placenta, some pathogens are capable of 
overcoming these placental defenses and induce devastating consequences to the developing fetus. 
These pathogens are collectively referred to as TORCH pathogens with the acronym referring to 
Toxoplasma, Other (Zika virus, Listeria monocytogenes, Treponema pallidum, varicella zoster 
virus (VZV), human immunodeficiency virus (HIV), and others), rubella virus, cytomegalovirus 
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(HCMV), and herpes simplex virus. To understand how these pathogens cause fetal disease, it is 
important to consider routes of entry to the fetal compartment and methods of evading the intrinsic 
defenses and barriers of the maternal-fetal interface. Several different models have been employed 
to study this evasion, including: immortalized trophoblast cell lines, primary trophoblast cultures, 
human tissue explants, and in vivo models. Each model has advantages and limitations, which must 
be understood to interpret and extrapolate the conclusions to human pregnancy. 
1.1.6.1 In Vitro Models to Study Human Placental Functions 
BeWo, JEG-3, and JAR cells are commonly used tractable trophoblast cell lines derived 
from choriocarcinomas. Although these cell lines all express trophoblast markers, they do not 
spontaneously fuse to form syncytia, and thus they are more suited to model either CTBs or EVTs 
and do not recapitulate the biology of the SYN layer. Accordingly, these cell lines do not 
recapitulate the microbial resistance phenotypes observed in primary trophoblasts or placental 
explants [74, 76, 86]. BeWo cells can be compelled to syncytialize by treatment with agents that 
increase cAMP levels to enhance the expression of endogenous retrovirus fusion proteins 
responsible for CTB fusion [87], however, the elevation of intracellular cAMP levels can produce 
other phenotypes and these cells still remain susceptible to microbial infection [74]. In comparison, 
JEG-3 cells grown in a three-dimensional bioreactor-based system co-cultured with human 
endothelial cells spontaneously fuse to form SYNs and are able to recapitulate resistance to T. 
gondii and viral infections, as well as the constitutive release of type III IFN-λ [86, 88]. Primary 
human trophoblasts are excellent cellular models of CTBs and SYNs. However, the lack of 
efficient means to genetically manipulate these cells, coupled with their limited (usually 3-5 day) 
lifespan post-isolation, limits their utility. Ex vivo placental explants maintain the unique 
morphological structure of the placenta as well as the multicellular complexity and can be isolated 
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at all stages of pregnancy [89]. However, procurement of placentas from early to mid-gestation is 
complicated by increasingly restrictive government regulations. Indeed, several countries and 
states within the United States have illegitimized medical research using fetal-derived tissue, 
which includes the placenta, and other localities have limited access to tissues obtained from 
elective terminations.  
1.1.6.2 In Vitro Models to Study Human Decidual Functions 
While the above-mentioned models can provide valuable information regarding specific 
trophoblast-pathogen interactions and trophoblast-intrinsic immunity, they lack the maternal 
component. As with trophoblast models, there are a variety of different endometrial epithelial cell 
lines available for studies; with particular lines better suited as models for particular regions of the 
endometrium (such as glandular vs luminal models) [90]. Primary stromal cells can be obtained 
and are capable decidualizing in culture. Co-cultures of endometrial stromal cells and trophoblasts 
are used to model implantation [91, 92]. These models have limitations, including the exclusion 
of maternal immune cells that also comprise up to 40% of the decidua. Studies using ex vivo 
decidual explants are able to model the multicellular composition (including dNKs and decidual 
macrophages) and three-dimensional structure better, and recent congenital transmission studies 
using this model have provided insight into the decidual innate immune response and mechanisms 
of viral transmission [93, 94].  
1.1.6.3 Animal Models 
Animal models are necessary to understand the dynamic immunological complexities of 
maternal-fetal tolerance, inflammation at the maternal-fetal interface, and the disruption of 
tolerance associated with congenital infections. Although a number of studies on placenta biology 
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have come from experiments in mice, other animal models also have provided insights. Commonly 
used in vivo models include nonhuman primates (NHPs), sheep, and rodents [95]. As might be 
expected, NHPs are good models for human pregnancy, as there are many common characteristics 
including a hemochorial placenta, singleton pregnancies, and a long gestation period comparable 
to human pregnancy [95]. However, these models are ethically challenging, may be difficult to 
access or generate for some researchers, and are costly. Sheep also are commonly used to study 
placental vasculature since their villous trees are shaped similarly to that of humans [95]. However, 
placentation is different in sheep; in particular, the depth of implantation is minimal (with no 
trophoblast invasion through the endometrial epithelium), and there is a greater degree of 
separation between the fetal and maternal vasculature (epitheliochorial placenta). Rodents, and 
specifically mice, are the most commonly used animal models. Among rodents, the guinea pig 
shares more similarities with human pregnancy than the mouse, including: the source and levels 
of progesterone produced, deep trophoblast invasion, and long gestation (around 3-times the length 
of mouse gestation).  
Nonetheless, the most commonly used animal model for studying congenital transmission 
is the mouse, because it facilitates the use of many valuable immunological tools and techniques, 
has a short gestation period and large litter size, which enables a robust sample size, and is 
relatively inexpensive. Murine models are particularly advantageous in the context of genetic 
deficiencies (on the maternal or fetal side of the interface) and results from these animal studies 
can be complemented with data from human models. The use of the mouse model for congenital 
infections has elucidated some of the mechanisms by which pathogens cause congenital disease. 
Experiments on Listeria-induced fetal wastage have demonstrated the importance of maintaining 
maternal tolerance toward the fetus; where promoting the accumulation of fetal-specific CD8+ T 
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cells in the decidua causes fetal resorption, and most of the damage to the fetus is likely the result 
of a loss of maternal tolerance, rather than the maternal response necessary to control the bacterial 
invasion [96]. A similar phenomenon has been described in Salmonella-induced placental 
inflammation; where the host response upsets the balance of maternal tolerance and leads to fetal 
loss [97].  
However, when studying congenital infections, it is important to consider that many 
TORCH pathogens are species-specific, and mice may lack susceptibility. Each model must be 
interpreted carefully, keeping in mind its limitations. One example is the use of a mouse pathogen 
analogous to the human TORCH pathogen; such as the use of the mouse cytomegalovirus 
(MCMV) as a substitute for HCMV. It is important to note, though, that  MCMV cannot cross the 
placental barrier (unlike HCMV) [98]. Another approach to overcome the barrier of host-
specificity is the use of immunocompromised mice, such as studies on Zika virus that use mice 
lacking the receptor to type I interferon [78, 99, 100]. Likewise, there also exists variability in both 
susceptibility and immune response between inbred strains of laboratory mice, as has been shown 
with Listeria [101]. Notwithstanding these issues, mice are still a highly useful tool and have 
provided much insight on the complexity of the maternal immune response during congenital 
transmission. 
1.1.7  Summary of Immune Responses at the Maternal-Fetal Interface 
Placentation is a common strategy employed by eutherian mammals to generate a conduit 
and barrier between the maternal and fetal environments. The variety of strategies employed to 
support placentation across the breadth of placental mammals is particularly interesting. Humans 
and mice both rely upon hemochorial placentas, but the structure and tissue organizations are 
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distinct. While the composition of the decidua is similar between mouse and human, the timing 
and mediators of decidualization are disparate. Through millions of years of evolution, each 
species has optimized the complex immunological equilibrium that is required to sustain healthy 
pregnancy. Therefore, both the advantages and limitations of various models should be considered 
when extrapolating data to human congenital transmission and disease. Although no model is 
perfect, biological insights can be obtained through the continued use and development of in vitro, 
ex vivo, and in vivo models. Collectively, these systems will provide new paradigms for one of the 
most unique aspects of human biology and, potentially, strategies to protect the developing fetus 
from potentially devastating congenital disease.  
1.2 Toxoplasma gondii Biology 
Toxoplasma gondii was initially discovered in 1908 by two independent research groups, 
Nicolle and Manceaux in Tunisia and Splendore in Brazil [102]. Both groups originally believed 
it to be a species of Leishmania, however in Nicolle and Manceaux soon realized it to be a novel 
protozoan and bequeathed it the name Toxoplasma gondii: toxo referring to the arc or bow-shape 
of the parasite, plasma meaning shape, and gondii for the hamster-like rodent in which it was 
initially found [102]. As Toxoplasma gondii is the only species within its genus, it is frequently 
referred to simply as Toxoplasma.  
Today, Toxoplasma is classified as a member of the phylum Apicomplexa. Characterized 
by their polarized cell structure consisting of an intricate apical arrangement of specialized 
organelles, all apicomplexans are single-celled, obligate intracellular parasites. In addition to 
Toxoplasma, other Apicomplexans of note for either notoriously causing disease in humans or for 
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their high synteny with Toxoplasma (useful for comparative genomic studies) are the malarial 
parasites in the genus Plasmodium and the cattle parasite Neospora caninum, respectively. 
1.2.1  The Parasitic Life Cycle of Toxoplasma 
Toxoplasma is a fascinating parasite, capable of infecting any nucleated cell and possessing 
a vast range of hosts that includes humans and other warm-blooded animals [102, 103]. This 
phenomenon is attributed to the parasite synthesizing and injecting its own receptor, RON2, into 
target cells. The secreted RON2 localizes to the host cell plasma membrane where it projects 
outward and binds to AMA1 on the parasite’s surface. This interaction then allows the parasite to 
create an invagination of the host plasma membrane and concurrently invade [104, 105]. The 
parasite relies upon asexual replication for propagation in most warm-blooded animals 
(intermediate hosts), while sexual replication is restricted to the gut epithelium of felids (the 
definitive host) for as-yet-unknown reasons [106–110]. Toxoplasma is capable of clonally 
maintaining its population for infinite generations solely within intermediate hosts, or bypassing 
the intermediate host to continuously infect definitive hosts (Figure 5). Thus, there are several 
routes by which the Toxoplasma may be transmitted to a new host via its three infectious life-
forms: the sporozoite that matures within oocysts shed into the environment, the fast-replicating 
tachyzoite, and the slow-growing bradyzoite found in tissue cysts.  
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Figure 5 The Parasitic Lifecycle of Toxoplasma 
The definitive host for Toxoplasma is the felid. Specifically within the gut of the felid, the parasite is able to sexually 
replicate. Progeny from sexual replication is then shed into the environment where they can be inadvertantly consumed 
by various intermediate hosts. During infection of intermediate hosts (which is composed of a wide range of warm-
blooded animals), the parasite asexually replicates and is transmitted between intermediate hosts and back to the 
definitive host via carnivorism. 
 
The sporozoite, or progeny of sexual replication, is enclosed within the oocyst and shed 
from an infected felid into the environment. There, it can be inadvertently consumed by another 
felid (to possibly repeat the sexual life cycle) or by an intermediate host (upon which it will enter 
the asexual life cycle). Oocysts must be matured before they are infectious, and this process occurs 
1 to 5 days post cat excretion [111], however, these oocysts can persist as infectious entities in the 
environment for as long as a year post deposit [112]. A single oocyst contains 2 sporocysts, that 
mature to form 4 sporozoites each [111].  Upon entering the digestive tract of the intermediate 
host, these sporozoites invade the gut epithelium and subsequently become tachyzoites.  
The tachyzoite is the fast (asexual) replicating lifeform. Physically characterized by its 
curved, arc shape, it is around 5µm by 2µm in dimension and follows a well-defined lytic cycle 
(detailed in the next section). This lifeform is the easiest to study and maintain in culture in vitro 
as it asexually replicates every 6 to 8 hours and can be maintained in this manner indefinitely 
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[113]. This quick-replicating, invasive form disseminates throughout the host’s body during the 
acute phase of infection. Meanwhile, the host immune system begins to mount a response to 
control the parasitemia, and this immunological pressure promotes conversion to the slow-growing 
bradyzoite form [114–116].  
Bradyzoites are the slow-growing, persistent lifeform of the parasite that form tissue cysts 
[111]. In immunocompetent animal studies, bradyzoite conversion is typically seen a week post-
infection [117], and the resultant tissue cysts are primarily located in muscle and central nervous 
tissues [111]. They range in size from 10µm-100µm and contain anywhere from two to over a 
thousand parasites [111]. In vitro studies have found that bradyzoite conversion can be induced by 
environmental stressors, such as alkaline pH [118, 119], arginine depletion [120], and heat shock 
[118], but bradyzoite development can also be spontaneous [121] and is particularly favored within 
certain cell types, like neurons and muscle cells [122–124]. These tissue cysts are refractory to 
drug treatment and assumed to reside within the host for the remainder of the host’s lifetime [114, 
117]. The tissue cyst wall also allows the bradyzoites to survive ingestion and to infect the gut 
epithelium of its new host [111]: either the cat, where sexual replication can proceed or another 
intermediate host to resume asexual replication. However, that is not to say that the bradyzoite is 
incapable of converting back into the virulent tachyzoite within the same host. Rather, clinical 
observations and in vivo animal studies suggest the bradyzoite is capable of sensing and taking 
advantage of signs of decreased immunological pressure from the host: for example, it is common 
for AIDS patients to suffer from relapsing toxoplasmosis [125, 126], as it is known that interferon-
γ (IFNγ)-secreting T cells are required to suppress and maintain chronic infection [127]. Likewise, 
chronically infected mice experience parasite reactivation following T cell depletion [127] and/or 
IFNγ suppression [128–130]. 
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1.2.2  The Tachyzoite’s Lytic Cycle 
During primary infection, T. gondii actively replicates and invades various tissues as part 
of its lytic cycle; eventually, though, the host immune system is able to control the infection and 
confine the parasite to intracellular cysts. The tachyzoite’s lytic cycle is a well-orchestrated process 
of attachment, invasion, parasitophorous vacuole (PV) formation, replication, and egress (Figure 
6). Moreover, this process is very fast: a tachyzoite can firmly attach, penetrate, and establish a 
PV in less than 30 seconds [131].  
 
Figure 6 The Tachyzoite’s Lytic Cycle 
The tachyzoite’s lytic cycle begins with (1) attachment onto the host cell surface and a primary secretion event. (2) 
The tachyzoite then invades the host cell by creating an invagination of the the host plasma membrane. (3) The 
resulting parasitophorous vacuole associates with host endoplasmic reticulum and mitochondria. (4) The tachyzoite 
asexually replicates via endodyogeny within the parasitophorous vacuole. (5) Evenutally, the parasites will lyse out 
of both the parasitophorous vacuole and the host cell; ready to begin the lytic cycle again. 
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 The attachment process begins when the extracellular tachyzoite glides to its new host cell 
and makes surface contact via non-specific interactions between parasite surface antigens and 
sulfated proteoglycans at the host cell surface [132]. Various effector molecules are secreted into 
the host cell and help to form a tighter connection and the moving junction (the mobile interface 
of the host cell and actively invading parasite during the invasion process). Key effector molecules 
that make up the moving junction are the parasite’s apical membrane antigen 1 (AMA1) and a 
complex of rhoptry neck (RON) proteins [133]. Anchored in the parasite’s plasma membrane, 
AMA1 interacts with the RON complex embedded within the host cell membrane.  
As the parasite invades, it forces its way through the moving junction into a newly formed 
invagination of the host cell membrane [134]. In the process of creating this PV from the host 
cell’s plasma membrane, the moving junction also acts as a molecular sieve to exclude embedded 
host proteins [135]. During infection, the PV closely associates with the host ER and mitochondria 
[136]. Throughout this process, the PV is nonfusogenic and does not acidify; thus serving as a 
protective barrier throughout infection [137].  
Within its PV, the successful tachyzoite invader can now commence with its asexual 
replication via endodyogeny [138–140]. Endodyogeny is an asexual replicative process by which 
two daughter cells are assembled within a mother cell. Ironically for a parasite, the daughter cells 
essentially consume the mother cell from the inside out (Figure 7). The anterior end of the 
daughter cells is synthesized first (inner membrane complex), and as replication proceeds, the 
maternal nucleus and organelles are split between the two nascent daughter cells. Upon completion 
of this internal partitioning of the mother cell contents, the progenitor cell’s inner membrane 
complex dissolves and the remaining maternal plasma membrane is cleaved in two, beginning at 
the anterior pole. Consequently, the daughter cells maintain a tenuous connection via maternal 
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residue at the posterior pole; this tether gives a cluster of synchronous, replicating tachyzoites its 
characteristic arrangement in a rosette pattern (Figure 7) [139, 141]. In vitro, the tachyzoite 
undergoes endodyogeny every 6 to 8 hours [113]. After 6 or 7 rounds of replication the parasites 
egress [113], causing lysis of the host cell [142]. Thus, one parasite can produce 64 to 128 
tachyzoites during infection of a single cell. Egress can be triggered by a variety of intrinsic and 
extrinsic triggers, such as the pH of the PV dropping below a certain threshold or activation of the 
extrinsic host cell death pathway [133]. The egressing tachyzoites will then disseminate from the 
site of infection to invade other tissues. 
 
Figure 7 Endodyogeny 
Asexual replication of Toxoplasma. (A) Illustration of endodyogeny. First the inner membrane complex of the 
daughter cells forms within the mother cell. Organelles are divided between the two developing daughter cells. The 
process is completed as a furrow forms between the daughter cells, dividing the plasma membrane. (B) Repeated, 
synchronized endodyogeny results in the formation of a rosette of parasites with leftover maternal residue at the center. 
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1.2.3  Host-Parasite Interactions 
In order to successfully infect and propagate, Toxoplasma secretes various proteins into the 
host cell. Secreted proteins are organized into specialized secretory organelles that release their 
contents in an orderly fashion during invasion and intracellular replication. Proteins secreted after 
parasite invasion must also cross the PV membrane in order to gain access to the host cytoplasm 
and nucleus. 
1.2.3.1 Specialized Secretory Organelles in Toxoplasma 
The ultrastructure of the parasite is illustrated in Figure 8. Notably, Toxoplasma possesses 
three kinds of specialized secretory organelles: micronemes (“little threads”), rhoptries (“club-
shaped”), and dense granules (named for their electron-dense appearance in transmission electron 
micrographs). These specialized secretory organelles are discharged in a particular order during 
infection. Most proteins secreted via one of these organelles follow a simple naming convention 
in accordance to their organelle of origin: microneme proteins are designated as “MICx”, rhoptry 
neck proteins as “RONx”, rhoptry bulb as “ROPx”, and dense granules as “GRAx”; “x” 
representing a number in its order of identification [143]. In the tachyzoite life stage, the 
micronemes and rhoptries are positioned near the conoid; in contrast, the dense granules have a 
scattered distributed within the cell.  
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Figure 8 The Tachyzoite Ultrastructure 
The Toxoplasma tachyzoite possesses three types of specialized secretory vesicles: micronemes, rhoptries, and dense 
granules. Like other eukaryotic cells, the tachyzoite has a nucleus, endoplasmic reticulum, and Golgi body. There is 
also a single long mitochondrion. The apicoplast is a non-photosynthetic plastid common amongst organisms in the 
phyllum Apicomplexa. Along most of the inner periphery of the tachyzoite is the inner membrane complex; which 
consists of membrane sacs flattened into sheets. 
 
Secretion is temporally regulated in a cascade that is initiated upon the parasite’s 
attachment to a host cell [144]. During the first, transient attachment, microneme contents are 
discharged through the conoid, releasing microneme adhesions that assist with firm attachment 
and creation of the moving junction. Also contributing to the moving junction is the contents of 
the rhoptry neck (the RON complex), which are discharged around the same time. Next to be 
secreted is the cargo of the rhoptry bulbs, initializing the formation of the PV. Infections performed 
in the presence of the cytochalasin D (an actin inhibitor that prevents parasite invasion, but not 
attachment and initial injections) illustrated that these early secreted proteins are capable of 
forming small vacuoles (evacuoles) possessing properties similar to that of the real PV: tightly 
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associating with the endoplasmic reticulum and mitochondria while non-fusogenic with the host’s 
endosomes nor lysosomes [145]. After invasion and formation of the parasitophorous vacuole, the 
dense granules begin to release their cargo and will continue to do so throughout the rest of the 
infection [144]. Unlike the other secretory organelles, the dense granules do not secrete their 
contents near the conoid [146]. Instead, they penetrate the inner membrane complex to fuse with 
the outer membrane. GRA proteins will then be targeted to the PV vacuolar network, associated 
with the PV membrane, or exported out of the PV into the host cell. 
1.2.3.2 Exporting Proteins Beyond the PV Membrane 
While the PV membrane forms a seemingly impenetrable barrier segregating the host cell’s 
cytoplasmic contents from the replicating tachyzoites, an increasing number of Toxoplasma dense 
granule proteins have been identified that transverse this barrier and even enter the host cell 
nucleus [147–151]. At first, GRA17 and GRA23 were suspected to form this protein export 
machinery due to their shared homology with known Plasmodium PTEX (Plasmodium translocon 
of exported proteins) components, however, this function was not found to be conserved in 
Toxoplasma [152]. Instead, these two proteins only facilitate the translocation of small molecules 
(<3 kDa) across the PV membrane. Recently, the MYR family of proteins have been identified as 
the true components of the Toxoplasma translocon for protein exportation [153, 154]. MYR1, 
MYR2, and MYR3 are localized to the PV membrane and deletion of either one has been shown 
to disrupt protein export [153, 154]. Furthermore export into the host cytoplasm is dependent upon 
the translocating protein’s structure, or rather its absence thereof [154–156]. 
Unlike its relative Plasmodium which has the ability to unfold highly structured proteins 
in order to secrete them beyond the PV membrane [157], the Toxoplasma PV translocon (of which 
the MYR family is believed to be a part) relies upon the unstructured nature of the secreted proteins 
 35 
themselves [154–156]. Thus, only disordered proteins may be funneled through Toxoplasma PV 
membrane. This scheme for secreting factors into the host cytoplasm decreases the energy 
expenditure, and it may explain the observation that many GRA proteins are intrinsically 
disordered and lack obvious catalytic domains [156, 158]. Investigation of GRA16 also suggests 
that there could be an additional advantage to these disordered GRA proteins [147]. GRA16 was 
one of the first dense granule proteins found to not only cross the PV membrane but also enter the 
host cell nucleus, where it interacts with several host factors to regulate the p53 pathway and hijack 
metabolism and cell cycle progression [147]. These activities are mediated by the presence of short 
linear motifs (SLiMs) of no more than 11- and no less than 3-contiguous amino acids long [159, 
160]. SLiMs may serve as nuclear localization signals, protease cleavage sites, docking sites, etc. 
Their short size is evolutionarily advantageous as they may arise (or disappear) with a single point 
mutation [161–163]. Thus, Toxoplasma gains several benefits from utilizing a translocon whose 
substrates are intrinsically disordered. 
1.2.3.3 The IFNγ Response and Parasite Countermeasures 
While Toxoplasma can productively infect practically any nucleated cell in vitro [142], 
IFNγ-primed tissue cultures are capable of significantly resisting infection [164–168]. This 
dependence on IFNγ to control T. gondii is also seen at the organismal level, where the host 
immune system relies upon the production of IFNγ to control and limit the primary parasitemia 
[128, 169, 170] and control chronic infection [129, 130, 171, 172]. Herein is summarized the 
pathways of host recognition of Toxoplasma and the induction of IFNγ, the anti-parasite responses 
stimulated by IFNγ, and the known mechanisms by which the parasite is capable of evading this 
response. 
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Initial Detection of Toxoplasma Infection 
The robust IFNγ response to Toxoplasma infection can be considered to begin with the DC, 
whereby sensing of the parasite by its innate immune sensors leads to the induction of IL-12. In 
turn, IL-12 secretion amplifies IFNγ production by NK and T cells [173–175]. While IL-12 can be 
produced by several other kinds of immune cells, including macrophages, monocytes, and 
neutrophils, the initial secretion of IL-12 by the DC is ultimately critical for coordinating the 
amplifying cascade that culminates in high IFNγ production and the confinement of the parasites 
to quasi-dormant tissue cysts in the mouse model [176–181] (Figure 9).  
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Figure 9 Induction of IL-12 & Interferon-γ  
TLR activation of uninfected DCs leads to the induction of IL-12. IL-12 then further promotes IFNγ production by 
NK and T cells. Neutrophils also produce IFNγ, but it is through an as-yet-unknown IL-12 and MYD88 independent 
mechanism. Infected DCs activate T cells. As a result of IFNγ production uninfected cells become primed and able to 
kill subsequent parasite invaders. 
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To date, only two innate sensors haven been found to directly and specifically recognize 
Toxoplasma: Toll-like receptors 11 and 12 (TLR11, TLR12) [182–186]. Homodimers of TLR12 
or heterodimers of TLR11-TLR12 are located in the endolysosome where they bind Toxoplasma 
profilin and signal through the adaptor protein MYD88 to promote IL-12 induction. Profilin is an 
actin-binding protein essential for the parasite’s motility and host cell invasion process. As profilin 
is regularly shed from the parasite into the environment [182, 183] and can be endocytosed by host 
cells, this allows the DC to detect the parasite without physical contact. Mice with DCs deficient 
in TLR signaling exhibit low IL-12 production, and as a consequence, IFNγ production is reduced; 
resulting in an increased parasite burden [187].  
However, it is important to note that primates, birds, and cats do not express any homologs 
of TLR11 and TLR12 [188]. In the human genome, TLR11 is a pseudogene and no homolog of 
TLR12 exists. Furthermore, primary human monocytes and DCs can only induce IL-12 when in 
direct contact with live parasites; in contrast, their murine counterparts that can easily be stimulated 
with heat-killed or soluble extracts from Toxoplasma tachyzoites [189–191]. Yet, in these other 
species, the primary parasitemia is still effectively controlled. This suggests that various species 
have evolved their own mechanisms to recognize Toxoplasma infection [188]. 
Other TLRs, including TLR9 and TLR2, have been implicated in eliciting an immune 
response upon Toxoplasma infection, however they are hypothesized to only indirectly or 
nonspecifically recognize the parasite. For example, data suggests that TLR9 (which binds 
unmethylated DNA in the endolysosome) may become activated in response to commensal gut 
bacteria affected by the presence of Toxoplasma [186, 192–196]. These studies have found the 
role of TLR9 to be highly dependent upon the route of infection (oral versus intraperitoneal 
injection). [194, 197–199]. TLR2 has been proposed to nonspecifically recognize 
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glycophosphatidylinositol (GPI) anchors [200–203]. GPI is a posttranslational modification of a 
protein’s C-terminus that allows it to bind to the plasma membrane upon secretion, and is 
commonly found on the surface of various protozoans [200, 201, 204]. However, like TLR9, 
studies have found discrepancies in TLR2’s role depending upon oral or intraperitoneal injection 
routes of infection [194, 203, 205]. Furthermore, TLR2 activation does not majorly affect IL-12 
production, the main driver of downstream IFNγ [206]. 
Besides TLRs, the components of inflammasome activation have also been implicated in 
the early detection and control of Toxoplasma: the P2X7 receptor and NALP1. P2X7R is a 
membrane ion channel found on the cell surface of monocytes and macrophages and activated by 
extracellular ATP [207]. P2X7R in particular plays a large role in formation of the inflammasome, 
induction of apoptosis, and elimination of intracellular pathogens via phago-lysosomal fusion 
[208–212]. Studies have found that both human and mouse macrophages are capable of killing 
intracellular Toxoplasma upon P2X7R activation, mediated by reactive oxygen species (ROS) and 
enhanced targeting of the PV for lysosomal fusion [213, 214]. Human studies even suggest natural 
single nucleotide polymorphisms (SNPs) that render P2X7R functionality defective may make 
those individuals more susceptible to both acquired and congenital toxoplasmosis [214, 215]. 
Another innate sensor that may be triggered by Toxoplasma is the NOD-like receptor NALP1. 
Located in the cytoplasm, activation of NALP1 results in inflammasome assembly, secretion of 
IL-1beta and IL-18, and activation of the inflammatory cell death pathway pyroptosis. While the 
exact mechanism by which NALP1 is activated by Toxoplasma is not known [216], it may play an 
important role in IFNγ induction. The importance of NALP1 was first recognized in a screen for 
susceptibility markers for congenital toxoplasmosis, where some allelic variants are more closely 
associated with congenital toxoplasmosis [217]. In vitro experiments where NALP1 was knocked-
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down found parasite infection of these monocytes could no longer elicit IL-1beta, IL-18, and IL-
12 upregulation [217].   
Anti-Parasite Responses Induced by IFNγ 
Animal and in vitro studies have found IFNγ to be essential for controlling parasitemia and 
host survival [169, 179, 181, 218, 219], however the exact mechanisms that mediate control are 
still not fully understood. In vitro experiments have found IFNγ pre-stimulation makes the host 
cell inhospitable toward the intracellular parasite, either by attacking the protective PV, starving 
the parasite of essential molecules, or by diffusing across the PV to cause direct damage to the 
parasite itself. Importantly, the toxoplasmacidal effects of IFNγ are completely dependent upon 
priming before infection [220]. 
As mentioned previously, the PV is carefully formed upon invasion: while derived from 
the host cell membrane, the moving junction sieves-out and prevents the incorporation of a 
majority of host membrane proteins that could act as receptors for innate immune pathways. 
However, priming with IFNγ can stimulate expression of genes and noncanonical pathways that 
protect the host cell from the intruding parasite by attacking that carefully crafted PV. In murine 
cells, IFNγ induces expression of immunity-related GTPases (IRGs) and p67 guanylate-binding 
proteins (GBPs). These proteins are loaded onto the PV with the aid of several core autophagy 
proteins (such as the Atg5-Atg12-Atg16L1 E3 ubiquitin ligase complex) to disrupt the PV 
membrane [221–223]. The exposed parasites can then be quickly cleared from the cell cytoplasm. 
However, while the mouse genome has encoded 21 members of the IRG family and 13 GBPs, 
humans only have a single IRG homolog and 7 GBPs [224, 225]. Furthermore, in vitro studies 
have found most of the human GBPs to be nonessential for controlling Toxoplasma replication in 
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IFNγ-activated HAP1 cells [226]. Yet, a similar strategy may still be used by human cells; for 
example, Selleck et al found several core autophagy proteins to play important roles in controlling 
Toxoplasma via a noncanonical autophagy pathway [168]. Early components that label targets for 
autophagy (such as ubiquitin, p62, and LC3) are recruited to the PV and encased by multiple 
membranes, but never fuse with late endosomes or lysosomes. This suggests that while human 
cells may be capable of similarly targeting the PV, other mechanisms may also be at play.  
Another strategy IFNγ-primed cells employ is starving the parasites of essential molecules. 
The first such mechanism was identified in the 1980s by Pfefferkorn and colleagues [164, 227]. 
Spurred by the observation that higher doses of IFNγ were required to inhibit Toxoplasma 
replication when human fibroblasts were grown in Dulbecco’s media compared to Eagle’s media, 
they ultimately found IFNγ induces expression of indoleamine 2,3-dioxygenase (IDO). IDO 
degrades tryptophan to N-formylkynurenine, thus starving Toxoplasma of the essential amino acid. 
Another target for parasite starvation is iron; a study performed in primary IFNγ-activated rat 
enterocytes found Toxoplasma replication to be dependent upon the level of intracellular iron 
available [228].  
 Reactive oxygen and nitrogen derivatives are the third mechanism by which IFNγ 
stimulation can restrict Toxoplasma infection, specifically in macrophages. These molecules can 
easily diffuse across the PV to directly cause damage to the parasite in a non-specific manner. 
Upon phagocytosis of Toxoplasma, monocytes and macrophages respond with respiratory burst 
activity that is associated with mass killing of parasites within 6 hours [229]. In contrast, 
monocytes collected from individuals with chronic granulomatous disease (and thus oxidatively 
deficient) exhibited markedly less toxoplasmacidal activity [229]. Likewise, reactive nitrogen 
species have also been implicated in macrophage-mediated killing of Toxoplasma. 
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Toxoplasmacidal activity of IFNγ and LPS-activated macrophages has been demonstrated in vitro 
to be abrogated by the addition of a competitive inhibitor or L-arginine [230], and in vivo deletion 
of inducible nitric oxide synthase in the mouse model was found to be essential for controlling 
persistent, chronic Toxoplasma infection [231]. However, the production of reactive nitrogen 
species consumes the intracellular pool of arginine—an amino acid essential for Toxoplasma 
replication [120]. Arginine starvation also acts as trigger for tissue cyst formation and bradyzoite 
differentiation [120]. 
Parasite Manipulation and Evasion of the Host Immune Response 
It is interesting to note that all known mechanisms by which a cell can autonomously kill 
intracellular Toxoplasma require stimulation with IFNγ prior to infection. Post-invasion, the 
parasite is capable of effectively modulating the host cell’s responses in order to promote its own 
propagation and parasitic life cycle, including interactions with the host immune system. To persist 
within the ecosystem, it is advantageous for the parasite to both disseminate throughout the body 
of the host and elicit a strong host immune response. Rather than completely clearing infection, 
the antagonism of IFNγ ultimately confines the parasites to slow-growing tissue cysts in the 
skeletal muscle and brain. These pockets of parasites may then persist throughout the lifetime of 
the host. Thus, the infected host becomes the vector by which the parasite can pass onto its next 
host, via carnivorism. Toward this goal, Toxoplasma secretes various effector proteins into the 
host cell during invasion and intracellular residency. These effector proteins can manipulate the 
host cell by directly inhibiting innate cellular defenses, interfering with IFNγ receptor signaling, 
and manipulating interactions between immune cells.  
Obstruction of host IRGs’ ability to puncture the PV is a most notable example of the 
parasite’s capacity to directly inhibit key intrinsic cellular defenses. ROP18, a serine/threonine 
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kinase, is the primary virulence factor in vitro [232, 233]. By phosphorylating several key IRG 
proteins, it is able to prevent their oligomerization and subsequent loading onto the PV membrane 
[234, 235]. ROP5 is a pseudokinase that allosterically enhances the function of ROP18 and is also 
capable of independently preventing IRG oligomerization [236, 237]. Interestingly, while ROP18 
has a strong phenotype in vitro, its absence only moderately decreases virulence in vivo [233]; 
while on the other hand, ROP5 actually has a very strong in vivo phenotype [238]. It should be 
noted, though, that these virulence traits are strain-specific, as not all strains of Toxoplasma possess 
the virulent alleles of these genes [232, 233, 238, 239]. 
In addition to counteracting innate cellular defenses, Toxoplasma is also capable of making 
host cells unresponsive to IFNγ receptor signaling [240–242]; thus cells treated with IFNγ post-
infection do not exhibit any parasite growth restrictions. The dense granule protein TgIST (T. 
gondii inhibitor of STAT transcription) is a striking example of how the parasite is able to override 
the host cell’s normal response to IFNγ [149, 150]. Normally, upon binding of IFNγ with its 
receptor, STAT1 is phosphorylated, dimerizes, and translocates into the host cell nucleus. There, 
STAT1 will bind the promoter regions of interferon-stimulated genes (ISGs) and stimulate their 
induction [243]. However, TgIST interrupts this chain of events by binding both nuclear STAT1 
and the nucleosome-remodeling and deacetylase (NuRD) complex, resulting in an altered 
chromatin environment non-conducive for ISG induction [149, 150]. Strikingly, ectopic 
expression of TgIST alone is sufficient to prevent ISG induction in this manner [149], however, 
the particular mechanism by which this nucleosome alteration is not yet understood [156]. 
A third method by which Toxoplasma can manipulate and co-opt the host immune response 
is by GRA-influenced cytokine induction. Initially assumed to be limited to the PV, an increasing 
number of dense granule proteins (GRAs) have been shown to exert effects beyond the PV and 
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even translocate across the PV membrane to enter the host cell nucleus [147–151]. GRA15 was 
the first dense granule protein reported to exert activity beyond the PV to which it is bound: in 
particular, the variant encoded in the type II genome is known to activate the p65 subunit of NF-
kB and induce IL-12 [244]. While IL-12 induction may seem counterintuitive for the individual 
tachyzoite, the downstream production of IFNγ can be seen as a way for the parasite to control its 
own virulence, promote persistent infection, and increase the probability of transmission to the 
next host through carnivorism. To aid in parasite dissemination, another dense granule protein, 
GRA6, recruits monocytes and neutrophils via secretion of chemoattractants CXCL2 and CCL2. 
The exact mechanism by which GRA6 exerts this effect  despite being restricted to the PV is not 
completely known, but involves the activation of NFAT4 by direct interaction of GRA6 with the 
calcineurin activator calcium-modulating ligand [245]. Meanwhile, GRA24 is able to promote 
both the induction of IL-12 as well as CCL2 via the p38alpha MAPK pathway [148]. Thus, by 
activating the host immune system and specifically recruiting particular lymphocytes, Toxoplasma 
may hijack these lymphocytes in order to better disseminate throughout the host [246–248]. 
1.3 Congenital Toxoplasmosis 
The first recorded case of human toxoplasmosis was in 1939 [249]. A 3-day old infant 
presented with seizures, respiratory complications, spinal cord injury, and macular lesions and 
subsequently died by day 31. Brain lesions containing a crescent-shaped protozoan were found 
upon autopsy, and samples of these lesions were capable of causing similar lesions following 
intracerebral inoculation of rabbits and infant mice [249]. Ultimately, the infant was determined 
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to have died from toxoplasmic encephalomyelitis, a disease today recognized to have been 
congenital toxoplasmosis (CT).  
The rates of CT incidence vary across the globe, with an estimated 5-23 cases per 10,000 
live births in Brazil [250], 2.9 cases per 10,000 live births in France [251], and 0.5 cases per 10,000 
live births in the United States (likely an underestimate, as there is no routine, nationwide screening 
of CT in the United States) [252]. Vertical transmission of Toxoplasma can have devastating 
consequences: from miscarriage or still-birth to birth defects, such as developing blindness due to 
ocular toxoplasmosis or neurological defects, with the degree of disease severity varying according 
to the stage of pregnancy transmission occurred. Infection during the first trimester often results 
in miscarriage and at the third trimester, loss-of-vision and mental disabilities in surviving 
children. Infants with severe clinical signs of infection may present with hydrocephalus, 
chorioretinitis, and intracranial calcifications [253]. However, 75% newborns with CT are 
asymptomatic at birth, and may not develop deafness, epilepsy, or symptomatic ocular 
toxoplasmosis (most commonly typified as chorioretinitis) until months, years, or decades later 
[253]. This delay in presentation can inadvertently cause postponement of treatment and 
potentially increase the risk and severity of disease manifestation. Case-in-point, several 
longitudinal studies have found correlations between pre-natal and early post-natal treatment and 
improved prognosis years later [254, 255]. 
1.3.1  Diagnosis 
Cases of CT are typically diagnosed by serology and PCR [256, 257]. Risk of CT is 
determined by monitoring maternal seroconversion. When a previously Toxoplasma seronegative 
individual later tests positive, this indicates a current or recent exposure to the parasite: 
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Toxoplasma-positive IgM is indicative of an infection within the past several months, while IgG 
specific to Toxoplasma can be detected in the serum 1-2 weeks post infection and will be sustained 
indefinitely. Seroconversion during pregnancy thus serves as a risk marker for the possibility of in 
utero transmission to the fetus. Fetal infection can be confirmed by indirect and direct methods. 
Post-birth, the infant can be tested for the presence of Toxoplasma-specific antibodies or for the 
parasite directly by PCR of bodily fluids. PCR can also be used prior to birth on samples of 
amniotic fluid or fetal blood collected from cordocentesis, although these procedures carry their 
own risks to fetal safety [258]. As will be discussed later, in the event that a woman tested 
seropositive for Toxoplasma prior to pregnancy, transmission to the fetus is considered unlikely 
due to cross-protection [257]. 
1.3.2  Treatment 
The standard treatment for CT is a combination of pyrimethamine and sulfadiazine (P/S), 
supplemented with folinic acid [256, 259]. This drug is given to infected infants as well as pregnant 
women beyond the first trimester. Pyrimethamine and sulfadiazine are competitive inhibitors of 
key enzymes in Toxoplasma’s folate metabolism; while folinic acid is commonly given to 
ameliorate the side effects of pyrimethamine on the patient. This drug combination is the most 
effective and standard treatment for toxoplasmosis, but cannot be given to women in the first 
trimester of pregnancy for risk of teratogenic side effects on the developing fetus [259]. In these 
cases, spiramycin is the drug of choice as it is considered nonharmful to the fetus and primarily 
concentrates in the placenta [259, 260]. The specific mechanism of action for spiramycin is not 
known, but it is hypothesized that it inhibits protein synthesis by the apicoplast [261]. Current 
consensus holds that due to its propensity to concentrate at the maternal-fetal interface, spiramycin 
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treatment during pregnancy functions more as a fetal prophylactic by preventing placental 
infection [262]. If there is still concern of fetal infection, after the first trimester, spiramycin may 
be supplemented or replaced with the standard P/S regimen [263].  
It is important to note that diagnosis, treatment, and prognosis all depend upon how soon 
the maternal seroconversion is detected. Numerous patient studies have found that the sooner 
treatment can be given, the better the potential prevention of CT or at least lessening of disease 
severity [253, 259, 263]. The importance of time in diagnosis and treatment may at least partially, 
if not completely, explain the differences in CT disease severity amongst patients in France versus 
the United States [264]. In France, a pregnant woman is routinely tested for seroconversion 
throughout the pregnancy [264]. Historically, France has had high seroprevalence among women 
of childbearing age (an estimated 83% of French women in 1965), and while seroprevalence has 
decreased (to 37% in a 2010 estimate), CT is still a national concern [251, 265, 266]. In contrast, 
seroprevalence amongst women in the United States is estimated to be only 9.1%, according to a 
2009-2010 survey [267], and routine testing for seroconversion is not standard [264]. Many cases 
of CT in the United States are not detected until later into the infection, when an abnormal fetal 
ultrasound is presented or even not until post-birth [264, 268]. Thus, timing of treatment for CT in 
the United States is more delayed, usually not given until after obvious fetal infection. Differences 
in disease severity can be seen in comparing follow-up studies of French [269–271] and American 
CT patients [272, 273], where a far higher percentage of American children will develop additional 
ocular lesions later in life, albeit still far better prognoses than seen in earlier studies with no 
treatments [273, 274]. 
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1.3.3  Transmission 
Classically, CT occurs as a result of in utero transmission of Toxoplasma during primary 
maternal infection, marked by maternal seroconversion. During pregnancy, the immunologically 
naïve mother may orally inoculate herself with Toxoplasma-contaminated food. Unwashed raw 
vegetables and fruits may be contaminated with highly infectious, sporulated oocysts shed into the 
environment by the cat. Consumption of undercooked meat is also a risk, as it can harbor 
Toxoplasma tissue cysts [257]. In most cases, if an expectant mother has previously been infected 
two or more months prior to conception, the primed immune system is able to prevent productive 
infection upon secondary exposure and there is little risk of transmission to the fetus [257, 259, 
260]. Whereas if the pregnant woman had not been previously infected, the parasite is able to 
disseminate un-checked, during which it may encounter the fetal compartment either upon further 
dissemination within the pregnant uterus or hematogenously as free tachyzoites or via infected 
leukocytes [74, 75, 275].  
While most cases of CT are linked to maternal seroconversion during pregnancy, there 
have also been rare reports of congenital transmission from women who were seropositive before 
pregnancy. Typically in such cases, the women are severely immunocompromised, such as with 
HIV, and experience reactivation of latent Toxoplasma that can lead to congenital transmission 
[276–278]. Interestingly, there are also reports of CT of an acquired secondary Toxoplasma 
infection from otherwise healthy, immunocompetent women due to highly virulent atypical strains 
[279–283]. An increasing number of reports have found the atypical strains of Toxoplasma, 
predominant in South America, to exhibit increased virulence resulting in more severe infections 
[250, 284, 285] with no cross-protection from primary infection with classical Toxoplasma strains 
seen in animal models [286, 287]. 
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1.3.4  Toxoplasma Genetic Diversity and Associations with Human Infections 
The Toxoplasma genome is haploid and consists of 65 x 106 base pairs arranged amongst 
14 linear chromosomes [288]. Most parasite populations are clonal with very little genetic 
variation, and these parasites can be phylogenetically organized into three lineages: type I, type II, 
and type III [289]. Differences in mouse virulence between the three classical Toxoplasma types 
has been used to map and identify virulence alleles: where type I is considered the most virulent, 
LD100=1 parasite; type II is of intermediate virulence, LD50=102-104 parasites; and type III is of 
least virulence, LD50=105-106 parasites [233, 290]. Atypical parasites are unrelated to these 
lineages and possess a combination of various alleles typically assigned to the three clonal 
lineages, as well as unique polymorphisms [291, 292]. Different atypical strains have been 
associated with high and low virulence, and extreme genetic variations makes mouse virulence 
difficult to predict [291]. Furthermore, virulence in mice does not directly correlate to virulence in 
other species, including other rodents [293].  
Amongst human toxoplasmosis cases, type II is the predominant lineage found in 
circulation within Europe, present in 64.1% of cases; while 12.5% and 9.4% of European 
infections are caused by types III and I, respectively [294]. Classically, North American parasites 
were believed to be highly clonal and similar to Europe, however, recent studies have found an 
increasing number of atypical strains: 43.9% atypical, 43.9% type II, and 12.2% type III [295]. In 
Central and South America, there are no predominant genotypes apparent and the majority of these 
parasites are classified as atypical strains [294]. In Africa, the degree of diversity is dependent 
upon region: North and East Africa are more similar to Europe (predominately type II and III), 
while tropical Africa displays more diversity and a predominance of atypical strains akin to that 
which is found in South America [296].  
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1.3.5  The Placenta as a Barrier to Toxoplasma Transmission 
The fetus’s first line of defense against vertical infection is the placenta. As previously 
discussed, the placenta is a formidable barrier that performs a myriad of duties, including 
protecting the fetus from any maternal pathogens. These functions are all orchestrated by the 
placental trophoblasts, which line the villous trees and directly contact the maternal tissues. 
Interestingly, recent studies with PHT cells and placental villous explants have found SYN to pose 
a formidable barrier against a range of infectious agents—including Toxoplasma [74, 75, 86]. 
However, congenital transmission does occur, and as the pregnancy progresses, there is an 
increased risk of transplacental transmission. During the first trimester, the probability of vertical 
transmission is 10-15%, but later in pregnancy, this risk increases to 30% during the second 
trimester, and 60% at the third trimester [259]. 
Based on the published data and current understanding of placental biology, several 
hypotheses could explain this phenomenon [297]. First, there is the correlation between increasing 
risk of transmission and increased placental contact with maternal blood [259]. Furthermore, 
Toxoplasma-infected monocytes have been shown to adhere more tightly to trophoblasts in vitro 
[275]. This close contact may increase the probability of hematogenous spread during maternal 
parasitemia. A second hypothesis proposes EVTs anchoring the placental villous trees to be the 
gateway for parasite dissemination into susceptible fetal tissues. In support of this idea, EVTs from 
first trimester explants have been found to be susceptible to Toxoplasma and may provide a route 
of entry into the villous core (and from there, the fetus itself) [75]. Third, damage to the 
Toxoplasma-resistant SYN layer exposes the susceptible underlying cells [74, 75]. As the placenta 
continues to grow throughout pregnancy, the late pregnancy placenta may present a larger target: 
with increased surface area, there may also be more opportunities for SYN damage that the parasite 
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can exploit. Despite its vital position at the maternal-fetal interface, the biology of placenta-
Toxoplasma interactions is not well understood, and more research is required to explain how 
Toxoplasma is able to overcome the placental barrier. 
1.4 Conclusions 
Globally, 70% of women of childbearing age are immunologically naive for Toxoplasma 
and at risk for primary infection. While the prevalence of Toxoplasma infections within specific 
regions can widely vary, risk of infection during pregnancy is a serious concern, especially in this 
era of increasing globalization. In countries that do not practice active surveillance for potential 
vertical transmission, congenital toxoplasmosis can be particularly devastating as a seemingly 
healthy pregnancy can result in miscarriage or birth defects. The placenta is the fetus’ first line of 
defense against vertically transmitted Toxoplasma. However, as the pregnancy progresses, the 
parasite is increasingly able to surpass this barrier. More research is needed to understand both the 
mechanisms that promote the placenta’s barrier function, as well as strategies employed by 
Toxoplasma to overcome this barrier and cause fetal damage. The data presented in the subsequent 
chapters seeks to address some of this gap in our knowledge of Toxoplasma infections during 
pregnancy. In Chapter 2, I define the barrier functionality of the SYN to T. gondii infection, while 
Chapter 3 is focused on understanding how the parasite elicits a strong immunomodulatory 
response. Specifically, I use CCL22 induction as a model to understand one of the unique 
responses induced during T. gondii infection of primary trophoblasts, a response that cannot be 
modeled in trophoblast cell lines. 
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2.0 Human Placental Syncytiotrophoblasts Restrict Toxoplasma gondii Attachment and 
Replication and Respond to Infection by Producing Immunomodulatory 
Chemokines  
Toxoplasma gondii is a major source of congenital disease worldwide, but the cellular and 
molecular factors associated with its vertical transmission are largely unknown. In humans, the 
placenta forms the key interface between the maternal and fetal compartments and forms the 
primary barrier that restricts the hematogenous spread of microorganisms.  Here, we utilized 
primary human trophoblast (PHT) cells isolated from full-term placentas and human mid-gestation 
chorionic villous explants to determine the mechanisms by which human trophoblasts restrict and 
respond to T. gondii infection. We show that placental syncytiotrophoblasts, multinucleated cells 
that are in direct contact with maternal blood, restrict T. gondii infection at two distinct stages of 
the parasite lytic cycle—at the time of attachment and also during intracellular replication. 
Utilizing comparative RNAseq transcriptional profiling, we also show that human placental 
trophoblasts from both the second and third trimesters respond uniquely to T. gondii infection 
when compared to trophoblast cell lines, typified by the up-regulation of several immunity-related 
genes. One of the most differentially induced genes was the chemokine CCL22, which relies on 
the secretion of a parasite effector(s) either during or after invasion for its induction. Collectively, 
our findings provide new insights into the mechanisms by which the human placenta restricts the 
vertical transmission of T. gondii at early and late stages of human pregnancy and demonstrate the 
existence of at least two interferon-independent pathways that restrict T. gondii access to the fetal 
compartment.  
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2.1 Introduction 
Toxoplasma gondii is a major source of congenital disease, with ~200,000 global cases of 
congenital toxoplasmosis reported each year [298]. In the majority of instances (~80%), in utero 
infections by T. gondii result in a range of severe birth defects, including ocular disease and 
developmental delays, and can also result in fetal death [299]. However, despite the clear impact 
of T. gondii infections on fetal health, the mechanisms by which the parasite is transmitted from 
the maternal bloodstream into the fetal compartment are largely unknown.  
In eutherian organisms, the placenta serves as the sole source of gas, nutrient, and waste 
exchange between the maternal and fetal compartments and acts as a key barrier to restrict fetal 
infections. At the forefront of these defenses is the syncytiotrophoblast (SYN), a multinucleated 
cell layer that comprises the outermost layer of the human placenta and which is in direct contact 
with maternal blood. Subjacent to the SYN layer are cytotrophoblasts (CYTs), mononucleated and 
proliferative cells that fuse to replenish the SYN layer throughout pregnancy. Together, these 
trophoblast layers form a primary barrier to the passage of pathogens that may infect the fetus by 
the hematogenous route.   
In general, the pathways that exist in the human placenta to limit the vertical transmission 
of microbes are poorly defined. Our previous studies in primary human trophoblast (PHT) cells 
have identified at least two potent antiviral pathways that restrict viral replication in trophoblasts 
[300, 301]. However, these pathways do not appear to be relevant during infection with non-viral 
pathogens, including T. gondii [77]. While studies in placental explants suggest that the SYN layer 
is not permissive to T. gondii infection [75], the mechanistic basis for SYN resistance is 
incompletely understood, as is whether the SYN layer mounts any innate defense in response to 
parasite exposure. Moreover, while placental explant models are useful in their recapitulation of 
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placental structure, they are limited in their capacity to dissect trophoblast cell type-specific 
pathways that might exist to limit T. gondii infection. 
In this study, we interrogated the trophoblast cell-type specificity of T. gondii infection 
utilizing PHT cells isolated from full-term placentas and identified two cellular mechanisms that 
mediate SYN-specific resistance to T. gondii infection. In addition to discovering that SYNs 
restrict T. gondii attachment and replication while CYTs do not, we also identified cell signaling 
pathways uniquely induced by parasite infection in PHT cells, which included the induction of 
several immunity-related genes. We show that the majority of transcriptional changes in PHT cells 
is specific to the human pathogen T. gondii and does not occur in response to infection with the 
closely related parasite Neospora caninum (which is not known to cause disease in humans). 
Moreover, we show that the production of one such uniquely induced immunity-related gene, the 
T regulatory (T-reg) chemoattractant CCL22, is dependent on host cell invasion and the secretion 
of T. gondii effectors into the host cell.  To expand our findings to earlier in human pregnancy, 
when the fetus is likely to face the more severe consequences of congenital T. gondii infections, 
we also utilized a mid-gestation chorionic villous explant model and show that second trimester 
SYNs also resist T. gondii attachment and induce CCL22 in response to infection whereas the 
fetal-derived amnion and chorion are permissive to infection and do not induce CCL22. Taken 
together, we have identified previously unknown intrinsic features in primary human placental 
cells from both the second and third trimesters of pregnancy that limit T. gondii infectivity at the 
level of attachment and replication, and provide details on both host- and parasite-specific 
transcriptional responses of placental cells to infection.   
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2.2 Results 
2.2.1  Syncytiotrophoblasts Isolated from Full-Term Placentas Resist T. gondii Infection  
We found that PHT cells isolated from full term placentas exhibited reduced susceptibility 
to T. gondii infection when compared to primary human foreskin fibroblast (HFF) cells (Figure 
10A, 10B). These data are consistent with our previous work demonstrating that PHT cells exhibit 
reduced susceptibility to infection by the three major types of T. gondii in North America and 
Europe compared to non-placental cells [86]. Importantly, human trophoblast cell lines (including 
BeWo, HTR8, and JEG-3 cells) were unable to recapitulate this restrictive phenotype and were 
permissive to parasite infection (Figure 10C, 10E). In addition, this phenotype was specific to 
PHT cultures as primary placental fibroblasts were as permissive to infection as HFF cells (Figure 
10D).  
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Figure 10 Trophoblast Cell Lines Do Not Recapitulate PHT Resistance to T. gondii Infection 
(A, B) Immunofluorescence microscopy of HFF and PHT cultures inoculated with T. gondii RH strain (green) at 
MOI=2 for 24 h. (A) Representative images of HFF (left) and PHT (right) cultures. Actin is shown in red; DAPI in 
blue. (B) Ratio of parasite to host cell areas based on immunofluorescence of five fields of view per culture; single 
PHT preparation. P=0.0064 based on 2-tailed T-ˇtest. (C, D) Growth curves of T. gondii CEP strain at MOI=0.5 in the 
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indicated cell types, as measured by luciferase expression by parasites. Growth over time is indicated in relative light 
units (RLU) as normalized to expression at 4 hpi; and represented by the mean of three samples plus standard 
deviation. (C) T. gondii growth in three different trophoblast cell lines (BeWo, HTR8, and JEG-3) as compared to 
HFF cells. (D) Comparison of T. gondii growth in primary cultures of HFF and PF (placental fibroblasts). (E) T. gondii 
(CEP) growth in HFF and BeWo cultures +/- 10 μM forskolin pretreatment at MOI=0.5 as measured by luciferase 
expression by parasites. Growth over time is indicated in relative light units (RLU) as normalized to expression at 
4hpi and represented by the mean of three samples plus standard deviation. At least two biological replicates were 
performed. 
 
PHT cells isolated from full-term placentas spontaneously fuse to form SYNs during their 
culture period (~72hrs), with some retaining a mononuclear CYT phenotype. Therefore, to 
determine whether the lack of PHT cell infection occurred in a cell-type specific manner, we 
infected PHT cells with YFP-tagged T. gondii (RH strain) and quantified parasite growth 
specifically in CYTs versus SYNs. These studies revealed dramatic differences in the 
susceptibility of SYNs and CYTs to T. gondii infection—whereas CYTs were permissive to 
infection, SYNs were highly resistant (Figure 11A, left). Furthermore, we observed that parasites 
within SYNs replicated to a lesser degree, as indicated by a highly significant reduction in total 
cell area occupied by parasites (Figure 11A). Since T. gondii replicates within a parasitophorous 
vacuole (PV) generated at the time of invasion by each individual parasite, the number of parasites 
within a PV can serve as an indicator of parasite growth and replication. In contrast to the PVs in 
CYTs, those in SYNs most often contained 1-2 parasites (Figure 11A, right). Importantly, fusion 
of BeWo cells with forskolin, which induces syncytin-mediated fusion [86], was not sufficient to 
confer resistance to T. gondii infection (Figure 10E), supporting that this phenomenon is specific 
to primary cells and does not rely on fusion alone.  
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Figure 11 Placental Syncytiotrophoblasts Resist T. gondii Infection 
(A) Left, immunofluorescence microscopy of PHT cells inoculated with T. gondii RH strain (green) for ~24h. 
Cytokeratin-19 is shown in red; DAPI in blue. SYN (outlined in cyan), CYT (outlined in yellow), and placental 
fibroblast (PF, outlined in white). PF cells are distinguished by the lack of cytokeratin-19 (red). Right, percentage of 
cell area occupied by T. gondii, as compared between CYT and SYN. NCYT=24, NSYN=9, from one preparation of PHT 
cells. 2-tailed T-test P<0.0001 with Welch correction for unequal variances. (B), Transmission electron microscopy 
of PHT cells infected with T. gondii (RH) for ~23hpi. Mononucleated CYT at left and SYN, identified by its more 
than two nuclei at right. Arrows indicate the parasites in the SYN. Scale bar is 2 µm. 
 
Transmission electron microscopy (TEM) revealed that whereas parasite growth and PV 
morphology were normal in mononucleated cells within the preparation (which are likely CYTs 
but could also be rare contaminating placental fibroblasts), SYN-internalized parasites were found 
within PVs containing host cell cytoplasmic contents indicative of a loss of vacuole integrity 
(Figure 11B).  Moreover, the parasites within these PVs contained more vacuoles of minimal 
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electron density and poorly defined organelles (Figure 11B). This phenotype is reminiscent of 
drug-induced death that we observed previously after treatment with a benzodioxole-containing 
compound [302], indicating that SYNs have potent Toxoplasmacidal activity. Taken together, 
these data implicate SYNs as an innately resistant cellular barrier to T. gondii infection and suggest 
that unlike other cultured cells, these cells potently resist T. gondii infection. 
2.2.2  SYN-Mediated Resistance to T. gondii Infection Occurs at Two Stages of the Parasite 
Lytic Cycle 
Our data suggest that SYNs restrict T. gondii infection at a stage of intracellular parasite 
growth. The primary mechanisms for cell-autonomous immunity to T. gondii are driven by the 
effector cytokine interferon γ (IFNγ). However, we found that uninfected and T. gondii-infected 
PHT cells had low levels of IFNγ transcript (Figure 12A) and that culture supernatants were 
devoid of secreted IFNγ protein (Figure 12A, 2B). Importantly, while the expression of GBP1 and 
GBP2 as well as other innate immunity-related factors (e.g., NOS1, 2 and IDO) have 
comparatively higher transcript levels in PHT cells (Figure 12A), none of these well-characterized 
IFNγ-driven host effector proteins were uniquely expressed in PHT cells (Figure 12A).  These 
findings suggest that the innate resistance of SYNs is not dependent on basal expression of IFNγ 
or its stimulation by infection. To explore other related mechanisms, we performed 
immunofluorescence microscopy for markers of autophagy- and lysosomal-mediated degradation 
pathways given the high level of basal autophagy we previously observed in PHT cells [301]. We 
found that there was no association between SQSTM/p62 or the lysosomal associated component 
LAMP2 and internalized parasites at either early or later stages of infection (Figure 12C and 
Appendix A, Figure 22). These findings are consistent with our TEM-based microscopic studies, 
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in which we did not observe the association between double membraned autophagosomes or 
lysosomes with internalized parasites (Figure 11B).  
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Figure 12 SYN-Mediated Restriction Of T. gondii Infection Is Not The Result Of Autophagy,  Lysosomal 
Degradation, Or Inability To Invade. 
(A) Heat-map of innate immune effector gene expression as determined by RNAseq of uninfected and T. gondii-
infected HFF, JEG-3, and PHT cells. (B) PHT cytokine secretion as detected by luminex assay of media from mock 
and T. gondii-infected PHT cells. Data shown is from one of two PHT preparations. (C) Immunofluorescence 
microscopy of PHT cells infected with T. gondii (RH) (green) at 8hpi. (Top) Infection with YFP-RH at MOI=10; p62 
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staining is shown in red. (Bottom) Infection with RH (anti-GRA2, green) at MOI=2; lysosome-associated membrane 
protein 2 (LAMP2) is shown in red; DAPI in blue. (D, E) Quantification of inside/outside staining of T. gondii (YFP-
RH) infected PHT cells at 2hpi, MOI=1 in one PHT cell preparation. Using DIC/DAPI images, cells were classified 
as mononucleated (CYT) or multinucleated (SYN). (D) To compare the attachment efficiency between cell types, the 
number of internalized parasites per 2D cell area was calculated for 813 cells (NCYT=729, NSYN=84) and the resulting 
distributions were compared using the Kolmogrov-Smirnoff test. The comparison used was: CYTinside vs SYNinside 
(P=0.010). (E) Comparison of percent invaded parasites of all parasites-associated cells by cell type ((NCYT=176, 
NSYN=34). 
 
In addition to the intracellular control of parasite replication, it is possible that SYNs are 
protected from infection by defects in parasite attachment and/or invasion. To quantify parasite 
attachment and invasion, we performed a two-step immunofluorescence-based invasion assay to 
distinguish extracellular from intracellular parasites (as in [303] and others). PHT cells were 
exposed to T. gondii (RH-YFP) for 2 hrs, at which point monolayers were washed to remove 
unbound parasites, cells were fixed, and attached parasites were identified using an antibody 
against surface antigen-1 (SAG1) in the absence of cell permeabilization, followed by detection 
using a secondary antibody conjugated to Alexa Fluor 594. Samples were then permeabilized and 
incubated again with anti-SAG1 antibody, which was detected with a secondary antibody 
conjugated to Alexa Fluor-633. Using this approach, extracellular parasites exhibited fluorescence 
in all channels (YFP, 594, and 633) whereas intracellular parasites exhibited fluorescence in only 
two (YFP and 633). Using differential contrast imaging (DIC) and automated image analysis, we 
quantified the extent of attached and internalized parasites in CYTs versus SYNs, which were 
easily distinguishable using DIC based upon the number, size, and clustering of their nuclei. Using 
this approach, we found that there were significantly fewer parasites overall (i.e., uninvaded and 
invaded) that were associated with SYNs compared to CYTs (normalized for cell area; p=0.010; 
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Figure 12D). However, the percentage of invasion events (of all total parasite associations) was 
nearly identical between SYNs and CYTs, demonstrating that while there is a significant defect in 
parasite attachment to and/or association with SYNs, there is no obvious impediment to invasion 
(Figure 12E).  While we do not know the stage of attachment at which T. gondii tachyzoites are 
arrested when associating with SYNs compared to CYTs, these data point to a defect in T. gondii 
attachment as a primary mediator of SYN resistance to infection in addition to their ability to 
potently resist parasite replication when the parasites do successfully invade.  
2.2.3  PHT Cells Have a Unique Response to T. gondii Infection Characterized by the 
Induction of Immunity-Related Transcription Factors and Chemokines 
Given the dramatic differences in infectivity and growth of T. gondii in PHT cells, we 
infected PHT cells or the choriocarcinoma JEG-3 cell line with T. gondii and compared their 
transcriptional responses to infection using RNAseq.  Following infection for 24 h, we identified 
401 transcripts of significantly different abundance (P<0.01; Fold-change>4) in infected PHT 
cells, and 106 transcripts of different abundance in infected JEG-3 cells (Figure 13A and 13B).  
To identify which transcripts were uniquely induced in PHT cells compared to JEG-3 cells and 
another primary cell line, we compared these data to a recently published RNAseq dataset from T. 
gondii-infected primary HFF cells [304].  While we identified 858 host cell transcripts that were 
of different abundance in T. gondii-infected HFFs, there was a significant lack of overlap between 
infection-altered transcripts in HFF and PHT cells (Figure 13B).  Cluster analysis of all genes 
induced in T. gondii-infected PHT cells revealed multiple categories of genes specifically induced 
in these cells and not in either HFFs or JEG-3 cells.  While some genes were induced uniquely in 
PHT cells and were expressed poorly in other cell types, (Figure 13A, cluster “a”), others were of 
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high abundance only after infection in PHT cells, but constitutively expressed in other cell 
lines/types (Figure 13A, cluster “b”).  Focusing on genes uniquely induced in PHT cells compared 
to other cell types (“Cluster 1”, Figure 13C), multiple immunity-related transcription factors (e.g., 
IRF4, EGR4), chemokines (CCL22, CCL17, CCL20, CCL1) and the chemokine receptor CCR7 
were all significantly induced by T. gondii infection. We confirmed this cell-type specific 
induction of a subset of the “Cluster 1” genes via RT-qPCR (Figure 13D). Of note, we found that 
CCL22, a chemokine known to be expressed constitutively during pregnancy [305, 306] and that 
has also been found to increase during miscarriage [305], was induced by >400 fold in infected 
PHT cells based on RNAseq and confirmatory RT-qPCR (Figure 13C and 13D).  Subsequent 
experiments with heat-killed T. gondii failed to induce CCL22 secretion from PHT cells (Figure 
13E), indicating that production of this chemokine requires live parasites and suggesting that the 
CCL22 response requires parasite invasion. Additional experiments treating PHT cultures with 
either neutralizing antibody to CCL22 or recombinant CCL22 showed no difference in the 
infection status of SYNs (Appendix A, Figure 23), providing support for the fact that CCL22 is 
not responsible for the reduced parasite attachment to or replication within SYNs compared to 
CYTs. This finding is consistent with the role of CCL22 as a chemoattractant rather than an 
effector cytokine like IFNγ.  
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Figure 13 PHT cells infected with Toxoplasma gondii have a unique transcriptional response to infection 
(A) Heat map of all genes with significantly higher transcript abundance in T. gondii-infected (I) PHT cells than in 
mock-infected (U) cells (P < 0.01; fold change, >4). (B) Genes with significantly higher abundance (P < 0.01; fold 
difference, ≥4) in PHT cells, HFFs, and JEG-3 cells. (C) Hierarchically clustered heat map of 40 genes induced in 
infected PHT cells. Cluster 1 contains genes that are induced in other cell types, while cluster 2 consists primarily of 
transcripts induced by T. gondii infection only in PHT cells (27/30). Transcription factors and chemokines and their 
receptors are indicated with asterisks. (D) qPCR validation of three genes specifically induced in T. gondii-infected 
PHT cells as identified by RNA-seq. Data shown consist of three technical replicates from an independent PHT cell 
preparation. (E) Induction of CCL22 secretion in PHT cells requires live parasites. Parasites were incubated at 23°C 
or 65°C for 1 h prior to being used to infect PHT cells. Data shown consist of two technical replicates from one PHT 
cell preparation. ***, P < 0.001 following one-way analysis of variance and multiple-comparison post hoc tests. 
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2.2.4  Infection of PHT Cells with Neospora caninum Does Not Induce the Production of 
Immunomodulatory Chemokines 
Host transcriptional responses to infection with T. gondii have been shown in a variety of 
cell types to be specific for T. gondii and are not associated with infection by one of its 
apicomplexan relatives, Neospora caninum [148, 153, 307]. Unlike T. gondii, N. caninum is not a 
human pathogen, but causes significant mortality in cattle and dogs and is associated with 
congenital disease in these animals [308, 309].  To determine the specificity of the host response 
to T. gondii infection in PHT cells, we infected cells with T. gondii (RH-YFP) or N. caninum (NC-
1-dsRED [310]) and compared the cellular responses to infection using RNAseq. We found that 
N. caninum failed to significantly induce any of the chemokine/chemokine receptor genes that 
were induced by infection with T. gondii of PHT cells (Figure 14A; asterisks indicate focus 
chemokine genes).  The remarkable lack of differential transcript abundance in N. caninum-
infected PHT cells compared to matched T. gondii infected PHTs was further illustrated by MA 
plot (Figure 14B).  In PHT cells, we identified 206 genes that were significantly induced by T. 
gondii infection (P<0.05; fold-induction>2), and only 10 genes that were significantly induced 
after N. caninum infection (Figure 14C).  Consistent with this, infection with N. caninum had no 
effect on CCL22 levels and co-infections with N. caninum and T. gondii showed that there was 
also no synergistic or additive effect (Figure 14D).  Importantly, despite the significant differences 
in gene induction, we found that PHT cells were similarly susceptible to N. caninum infection, 
with CYTs being readily invaded and supportive of parasite growth, while SYNs exhibited reduced 
invasion by and growth restriction of N. caninum in a fashion very similar to that observed for T. 
gondii (Figure 14E).   
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Figure 14 Infection-modulated gene expression is specific to T. gondii and requires parasite effectors 
(A) Heat map of 59 genes induced by at least 1.8-fold in PHT cells (P < 0.01) after infection with T. gondii (T.g.) RH 
strain (multiplicity of infection of 3). Raw count data were converted to normalized RPKM using DESeq2. Data are 
also shown for N. caninum (N.c.)-infected (n = 3) and mock-infected (n = 2) PHTs, and mean centered data were 
clustered by sample and gene using the Euclidean distance (implemented in MeViewer [TM4 microarray suite]; see 
Materials and Methods). Asterisks denote genes that are very highly induced in T. gondii-infected PHT cells. (B) MA 
plots of PHTs comparing gene expression profiles in mock- and parasite-infected cells for all 23,735 queried genes. 
Genes of higher abundance in uninfected cells are indicated by positive changes, and those of higher abundance in 
infected cells are indicated by negative changes. (C) In T. gondii-infected PHTs, 206 genes were found to be of higher 
abundance than in mock-infected cells, while only 10 such genes were found in N. caninum-infected PHTs, consistent 
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with the MA plots in panel B above. (D) Results from ELISA showing induction of CCL22 secretion in PHTs infected 
with T. gondii but not N. caninum. Host cells were infected with a multiplicity of infection of 2 (for each parasite 
species), and supernatants were harvested at the indicated time points. n = 2 to 3 wells for all treatments except for 
48-h T. gondii and T. gondii/N. caninum (n = 1); single PHT cell preparation. (E) PHTs were infected with NC-1-
dsRED N. caninum (multiplicity of infection of 3) for 24 h and stained with cytokeratin 19 antibodies and DAPI. 
Similarly to T. gondii, N. caninum grew efficiently in PFs (yellow outlines) and CYTs (white outlines) and poorly or 
not at all in SYNs (blue outlines). (F) CCL22 induction in PHT cells requires MYR1. PHTs were infected with either 
wild-type (WT) RH-YFP T. gondii, RHΔMYR1, or RHΔMYR1 complemented with a hemagglutinin-tagged copy of 
MYR1 (RHΔMYR1c). n = 3 for each T. gondii strain. Data shown are from one PHT cell preparation. 
2.2.5  CCL22 Induction in PHT Cells Requires the Toxoplasma gondii Dense Granule 
Protein MYR1  
Given that CCL22 induction in PHT cells required live parasites and was not induced by 
N. caninum, we reasoned that this induction likely resulted from a T. gondii-specific parasite 
effector that would be secreted after host cell invasion.  T. gondii MYR1 is a recently identified 
dense granule protein that is required for the export/secretion of multiple dense granule effectors 
(including GRA24, GRA25 and GRA16; [147, 148, 311]) and was discovered based on its role in 
mediating T. gondii-specific activation of the transcription factor c-Myc [153].  When we infected 
PHT cells with T. gondii lacking MYR1 (RH:ΔMYR1) and complemented control parasites 
(RH:ΔMYR1:MYR1c), we found that CCL22 production by PHT cells was entirely dependent upon 
MYR1 (Figure 14F), which provides strong evidence that T. gondii CCL22 induction in PHT cells 
is driven by (a) MYR1-dependent secreted effector(s).  
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2.2.6  Second Trimester Human Placental Villi Resist T. gondii infection and Induce 
CCL22 in Response to Infection 
Because PHT cells are isolated from term placentas, we next determined whether SYNs 
from earlier in human pregnancy also resist T. gondii infection and similarly induce immunity-
related genes. To do this, we utilized second trimester chorionic villous explants, which retain the 
morphology of human placental villi, including a layer of cytokeratin-19 positive SYNs covering 
the villi surfaces (Figure 15A). Consistent with our findings in PHT cells, and the work of others 
utilizing first trimester explants [75], we found that second trimester SYNs were resistant to T. 
gondii infection, even when infected with very high numbers of parasites (107) (Figure 15B, left 
panel). This resistance appears to be primarily at the level of parasite attachment as we detected 
very few internalized parasites in placental villi and most parasites detected appeared to be 
extracellular (Figure 15B, left panel, white arrows). Importantly, unlike placental villi, we found 
that fetal membrane (amnion and chorion) and maternal decidua supported T. gondii replication 
(Figure 15B, middle and right panels), highlighting the specific resistance of placental villi. In 
addition, consistent with the work of others utilizing first trimester explants [75], we found that 
CYTs subjacent to the SYN were permissive to T. gondii only when the SYN layer was breached 
(Figure 15C). These data show that the SYN layer also forms a barrier to T. gondii vertical 
transmission in mid-gestation.  
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Figure 15 Chorionic villous explants from the second trimester are resistant to T. gondii infection and induce 
similar cytokine profiles in response to T. gondii as do full-term PHT cells 
(A) Immunofluorescence microscopy of uninfected second-trimester placental villous explant with SYN localization 
indicated. Cytokeratin 19 in green; actin in red; DAPI in blue. (B) Immunofluorescence microscopy of midgestation 
villi (left panel), fetal membrane (middle panel), or decidua (right panel) inoculated with 107 T. gondii cells (RH 
strain) for 24 h. T. gondii in green; cytokeratin 19 in red; actin in magenta; DAPI in blue. White arrows denote single 
parasites in isolated villi and PVs in fetal membrane and decidua. (C) Immunofluorescence microscopy of 
midgestation villi inoculated with 107 T. gondii cells (RH strain) for 24 h. T. gondii in green; cytokeratin 19 in red; 
actin in magenta; DAPI in blue. Zoomed image from white box denotes PVs in CYTs located beneath a tear in the 
SYN (white arrow). (D and E) RNA-seq analysis of T. gondii-infected villous explants. Venn diagram (D) and heat 
map (E) showing a subset of genes that are similarly induced in one of the T. gondii-infected villous explants (explant 
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5) and PHTs. Genes were selected if they were at least 2-fold induced compared to mock infection and the value was 
significant using a DESeq2-determined adjusted P value of <0.05. Explant data in heat map are from 3 genetically 
distinct placenta preparations, while PHT data shown are the same as in Fig. 3. I, infected; U, uninfected (mock); 
FPKM, fragments per kilobase per million. Asterisks denote genes similarly induced in both explant 5 and PHT cells. 
(F) ELISA showing T. gondii (RH strain)-mediated enhancement of CCL22 secretion from villous explants at 24 h 
postinfection. 
 
Next, we profiled the transcriptional changes induced by T. gondii infection of second 
trimester chorionic villi using RNAseq to determine whether they responded to parasite infection 
similarly to PHT cells from late gestation.  We found that 172 transcripts were differentially 
expressed in response to T. gondii infection of villous explants, with 22 of these transcripts also 
being differentially expressed in response to infection of PHT cells, which included EGR3, EGR4 
and CCL22 (Figure 15D, 5E). We confirmed that CCL22 was induced at the protein level by 
ELISA in supernatants from T. gondii-infected second trimester villi (Figure 15F). These data 
suggest that CCL22 is specifically induced by the human placenta in response to T. gondii infection 
at both early and late stages of pregnancy.  
2.3 Discussion 
T. gondii infections present a worldwide threat to pregnant women, and there is an urgent 
need to develop novel treatment regimens to block congenital transmission of T. gondii and other 
pathogens that pose risks to the developing fetus. Our data presented here point to a direct role for 
SYN-intrinsic pathways in the protection of the fetus from T. gondii infection, making the SYN a 
highly unique cell type given that a diverse array of cells studied to date are susceptible to T. gondii 
 72 
infection and replication. A particularly remarkable feature of the PHT cell culture model is that 
there are both permissive and resistant cells in very close proximity, indicating that cell-
autonomous features determine the fate of T. gondii upon interaction with CYTs and SYNs.  Our 
studies in both human primary full-term and second trimester SYNs suggest that these cells evade 
T. gondii infection at two critical stages of the parasite lytic cycle—at the point of parasite 
association with the host cell and during intracellular growth. Moreover, by comparing cell-type 
specific transcriptional profiles from T. gondii infected primary trophoblasts and placental tissue 
with those of other cell types, we identified unique sets of genes induced by T. gondii infection in 
the human placenta, including the induction of CCL22 that requires the presence of parasite-
encoded MYR1. Collectively, our data provide significant advances in our understanding of how 
the human placenta controls, responds to, and is manipulated by, T. gondii infection.   
We found that the first point of SYN-mediated restriction of T. gondii infection occurred 
at the level of parasite association and/or attachment, which we observed both in SYNs isolated 
from full-term placentas and from mid-gestation chorionic villi. These findings are consistent with 
the previous work of others suggesting that attachment might be reduced in first trimester SYNs 
[75], although this was not directly tested. Our attachment and invasion data from PHT cells 
provide direct evidence that SYNs naturally restrict parasite attachment but are susceptible to 
invasion once parasite attachment occurs, which appears to be a rare event.  It remains unclear 
which point of the attachment process is altered when T. gondii associates with SYNs, but a likely 
stage is during the early phase of gliding motility prior to the second phase of attachment, (which 
is mediated by the secretion of microneme and rhoptry organelles [145]).  One possibility is that 
when parasites encounter SYNs they glide less efficiently than on CYTs or placental fibroblasts, 
which ultimately results in significantly reduced “full” attachment (mediated by microneme and 
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rhoptry secretions).  Differences in membrane biochemistry in SYNs versus CYTs and fibroblasts 
could underlie these important differences in early parasite association. Differences in 
glycosaminoglycan (GAG) content between CYTs and SYNs could also explain these differences 
given the known importance of GAGs in parasite gliding motility and attachment [312]. However, 
once secondary attachment occurs invasion seems to proceed normally, indicating that whatever 
membrane/surface differences there are between CYTs and SYNs, they do not impact the phase 
of invasion that requires organelle discharge.   
In mid-gestation chorionic villi, the poor association/attachment phenotype was even more 
profound than that observed in PHT cells, with little to no parasite association with the villi 
observed. These findings suggest that in addition to biochemical surface differences between 
SYNs and CYTs, the morphology of the SYN layer itself may directly impact parasite association 
and attachment.  This could be influenced by morphologic differences in this model, including the 
positive membrane curvature associated with the significant branching of the placental villous 
trees, which might impact lipid, protein and/or carbohydrate composition. In addition, the apical 
surfaces of SYNs associated with placental explants may be more differentiated than PHT cells, 
which might impact parasite attachment through the presence of a highly dense brush border in 
the explant model. Consistent with this, we previously observed very little T. gondii association in 
a bead-based three-dimensional cell line model of human SYNs, which also induces significant 
membrane curvature and allows for the formation of a well-differentiated brush border [86].   
For parasites that attach to the SYN layer, our data suggest a second level of resistance to 
infection that occurs post-invasion. Importantly, in contrast to other cells types, our data show that 
this resistance is not mediated by IFNγ, which is not basally expressed in PHT cells or induced by 
T. gondii infection. Furthermore, we did not find any evidence for autophagy- or lysosomal-
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mediated degradation pathways in the intracellular restriction of parasite replication.  To date, all 
known “cell-autonomous” mechanisms of parasite killing in human cells rely on previous 
stimulation with IFNγ. For example, IFNγ can induce a variety of downstream effector 
mechanisms depending on the cell type, including tryptophan starvation in HFFs [220] and 
decoration of the vacuole with guanylate binding proteins [313, 314], ubiquitin or other markers 
for autophagy including LC3B [314, 315].  Ultimately, these pathways would lead to lysosomal 
fusion with the parasite-containing vacuole and parasite destruction, which we did not detect in 
infected SYNs at any timepoint tested.  However, our data conclusively show that parasites that 
invade this specific trophoblast cell type are able to form what functional vacuoles, but are 
ultimately destroyed in a fashion reminiscent of some Toxoplasmacidal drugs [302, 316].  
Hallmarks of parasite killing are vacuolation of the parasites, breakdown of the vacuolar 
tubulovesicular network, and lack of integrity of the parasitophorous vacuolar membrane and 
leakage of host cytoplasmic contents into the lumen of the compromised vacuole.  These data place 
PHT cells, and specifically the subpopulation of fused SYNs, into a rare class of cells that not only 
restrict the growth of T. gondii after invasion in the absence of any external stimuli, but actively 
destroy invaded parasites.  While we did not compare them head to head with SYNs, neutrophils 
restrict T. gondii growth after invasion but are possibly less Toxoplasmacidal compared to SYNs 
given that neutrophils have been implicated in the spread of T. gondii throughout the intestine in a 
murine model [317].  Head-to-head comparisons between SYNs and innate immune cell types like 
neutrophils will help to illuminate what potential killing mechanisms might be shared, or not, 
between these cell types.  Moreover, determining the differences between SYNs and CYTs would 
require the development of new methods to separate them for downstream analyses including 
RNAseq and quantitative proteomics.   
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In addition to resisting T. gondii infection, our data show that PHT cells robustly induce 
the chemokine CCL22 in response to infection by a Myr-1 dependent effector secretion 
mechanism.  We do not know which cell types within the PHT preparation produce CCL22 after 
exposure to T. gondii, but given the dependence upon successful invasion for this response, a good 
candidate cell type is the CYT rather than the SYN, although cell-specific analyses are required to 
address this directly.  Importantly, the major inflammatory responses induced in PHT cells by T. 
gondii infection are not induced (or induced much more poorly) after infection with N. caninum, 
a near relative of T. gondii that does not successfully infect humans or rodents, suggesting that it 
may be a host and/or parasite adaptation that may impact disease outcome.   
The precise role of CCL22 in human pregnancy is unknown, but maternal cells express 
CCL22 at low levels throughout pregnancy, with increased levels associated with miscarriage 
[305]. Moreover, the induction of chemokines, including CCL22 and CCL17, are associated with 
preterm birth in humans [318] and in small animal models [319]. The precise role played by 
CCL22 during T. gondii vertical transmission remains to be determined.  However, exposure of 
PHT cells to recombinant CCL22 or CCL22 neutralizing antibody had no impact on parasite 
replication (Appendix A, Figure 23), supporting the idea that it has no direct anti-parasitic 
activity. A likely scenario is that the induction of CCL22, and other immunity-related genes, is 
aimed at alerting the maternal immune system to placental infection, where it could play any 
number of roles in mediating the dialogue between maternal and fetal tissues, such as enhancing 
immune cell-mediated protection at the maternal-fetal interface, or in terminating the pregnancy 
should levels reach a specific threshold. Given that CCL22 levels are elevated in maternal serum 
during healthy, infection-free pregnancies [305, 306], CCL22 and its recruitment of regulatory T 
cells may also play a role in immune tolerance throughout gestation, which is modulated in 
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response to infection. This increased T-reg recruitment may even promote T. gondii infection, as 
was seen in Listeria and Salmonella infections in the pregnant mouse model [320].  
Our findings provide important insights into the molecular and cellular pathways utilized 
by human SYNs at both late and mid stages of gestation to restrict T. gondii access to the fetal 
compartment. In addition, by characterizing the immunological pathways induced by T. gondii 
infection of SYNs, our findings have uncovered potentially novel biomarkers of infection severity 
that might have important roles in shaping the maternal systemic immune response.  These findings 
provide an example of the signaling crosstalk that exists between the maternal and fetal 
compartments and the mechanisms by which this signaling is impacted by parasite-associated 
effectors. Taken together, these findings provide important insights into T. gondii-induced 
congenital disease that could lead to the design of novel therapeutics aimed at reducing congenital 
toxoplasmosis.  
2.4 Materials and Methods 
2.4.1  Cell Culture 
All cell and tissue cultures were incubated at 37°C and 5% CO2 and all media were 
supplemented with 10% FBS and 50 µg/mL penicillin/streptomycin. JAR and HTR8 cells were 
grown in RPMI-1640 media (HyClone); BeWo cells in F-12K (Corning); and JEG-3 cells in 
Eagle’s Minimum Essential Medium (EMEM; Lonza). To induce fusion of BeWo cells, cells were 
treated with 10 µM forskolin for 24 hours, then washed with PBS before infection. Primary human 
trophoblast (PHT) cells were isolated from healthy, term-pregnancies, and were cultured as 
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described previously [300, 301]. PHT cells were cultured for ~48h prior to infection to allow for 
SYN formation. Primary placental fibroblasts were isolated and cultured as described previously 
[321].  
2.4.2  Mid-gestation Placental Explants 
Human placental tissue from less than 24 weeks gestation was obtained from the University 
of Pittsburgh Health Sciences Tissue Bank through an honest broker system after approval from 
the University of Pittsburgh Institutional Review Board and in accordance with the University of 
Pittsburgh anatomical tissue procurement guidelines. Chorionic villi, fetal membrane, and decidua 
were dissected and cultured in DMEM/F12 (1:1) supplemented with 10% FBS, 
penicillin/streptomycin, and amphotericin B. For T. gondii infections, isolated tissue was infected 
immediately following isolation with 2.5x104-1x107 parasites for ~24hrs. For imaging, tissue was 
fixed in 4% paraformaldehyde and imaging performed as detailed below.  
2.4.3  Parasites 
Type I (RH) and type III (CEP) T. gondii and N. caninum (NC-1) tachyzoites were used 
for this study. All parasites were maintained by continual passage in human foreskin fibroblast 
(HFF) cultures incubated at 37°C and 5% CO2 in DMEM supplemented with 10% FBS, 50 µg/mL 
penicillin/streptomycin, and 2mM glutamine. The YFP-RH was a gift from David Roos, and the 
RH-MYR1-KO and RH-MYR1-KO/complemented parasites were gifted by John Boothroyd. For 
infections, infected monolayers were scraped and syringe-lysed to release the tachyzoites. These 
parasites were then pelleted at 800 x g for 10 minutes, resuspended in fresh media, filtered through 
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a 5 µm filter, and counted to determine the appropriate dilution for infection. Mock inoculum was 
produced by filtering out the tachyzoites with a 0.2 µm filter.  
Parasite growth curves were generated by luciferase assay (Promega) using luciferase-
expressing CEP parasites. Briefly, at each time-point, samples were lysed using the passive lysis 
buffer (Promega) and stored at -20°C until at least 8h past the last time-point collection. Samples 
were then thawed and incubated with substrate, and fluorescence was measured. 
2.4.4  RT-qPCR and RNAseq 
RNA was isolated from cultures using the GenElute™ Mammalian Total RNA Miniprep 
Kit (Sigma) and the associated DNase digestion set (Sigma). Both a NanoDrop and an Agilent 
bioanalyzer were used to determine sample quality. Sequencing libraries were prepared from 0.2-
0.9 µg of total RNA by the TruSeq Stranded mRNA Library Preparation Kit (Illumina). The 
Illumina NextSeq. 500 was used for sequencing. CLC Genomics Workbench 9 (Qiagen) was used 
to map the RNA-seq FASTQ reads to the human reference genome (hg19). Differential expression 
analysis was performed using the Deseq2 package in R [322] using a significance cutoff of Padj < 
0.01, unless specified otherwise. Analysis of mock and T. gondii-infected HFF cells was based on 
datasets previously published and deposited into the Sequence Read Archive (SRA): 
SRR2644999, SRR2645000, SRR2645001, SRR2645002, SRR2645003, and SRR2645004.  
Hierarchical clustering of log2 transformed RPKM data was performed using MeViewer TM4 
software.  Data were either clustered as is or linearly mean centered using Euclidian distance.  
Color scales were adjusted for presentation purposes.  RNAseq data have been deposited in the 
NIH short read archive (accession numbers pending).   
 79 
For RT-qPCR analyses, RNA was isolated as described above and cDNA generated using 
the iScript cDNA synthesis kit (Bio-Rad), followed by qPCR using a StepOnePlus Real-Time PCR 
System (ThermoFisher). The ∆CT method was used to determine gene expression and normalized 
to the human actin CT of each sample. Primer sequences were as follows: Actin—
ACTGGGACGACATGGAGAAAAA (Forward, 5’-3’); GCCACACGCAGCTC (Reverse, 5’-
3’). CCL22—GTGGTGTTGCTAACCTTC (Forward, 5’-3’); GGCTCAGCTTATTGAGAATC 
(Reverse, 5’-3’). Pre-designed primers were ordered for CCL17 (Qiagen) and CCR7 (Sigma). 
2.4.5  Microscopy 
Cell monolayers and placenta explants were fixed in 4% paraformaldehyde and 
permeabilized with 0.1% Triton X-100 in 1x PBS. Primary antibodies were incubated for 1h at 
room temperature, followed by washing, then secondary antibodies conjugated to Alexa Fluor 
(Invitrogen) fluorophores for 30min at room temperature. Following washing, cells/explants were 
mounted with DAPI-Vectashield (Vector Laboratories) and imaging performed on an Olympus 
FV1000 laser scanning confocal microscope, a Zeiss LSM 710,  or an Olympus IX83 inverted 
microscope. In some cases, imaged were adjusted for brightness and contrast using Photoshop or 
Fiji/Image J. Image J was used for image analyses. Transmission electron microscopy was 
performed as described previously [301].  
Reagents and antibodies used for immunostaining studies include Alexa Fluor 594 or 633 
conjugated phalloidin (Invitrogen), cytokeratin-19 (Abcam), LAMP2 (Santa Cruz), SAG-1 (mouse 
monoclonal D61S; ThermoFisher).  
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2.4.6  CCL22 ELISA 
CCL22 ELISAs were performed with the human CCL22/MDC DuoSet ELISA (R&D 
Systems) as per the manufacturer’s instructions. 
2.4.7  Luminex 
Conditioned media from cells was analyzed by multiplex luminex by the University of 
Pittsburgh Cancer Institute (UPCI) Cancer Biomarkers Facility: Luminex Core Laboratory that is 
supported in part by award P30CA047904. 
2.4.8  Statistics 
All statistics were calculated using GraphPad Prism. Experiments were performed with 
independent preparations of PHT cells and second trimester villous explants. The data are 
presented as the mean ±SD. The individual statistical analyses and associated P values are 
described in the individual figure legends. 
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3.0 A Toxoplasma gondii dense granule protein GRA28 induces CCL22 in primary 
trophoblasts and cell lines of monocyte lineage 
Congenital toxoplasmosis is a serious concern during pregnancy, but little is known about 
interactions between Toxoplasma gondii and the placenta. Previously, we found placental 
trophoblasts induce the chemokine CCL22 specifically in response to T. gondii infection. In this 
current study, we identify GRA28 as the parasite effector necessary and sufficient for CCL22 
induction and lay the foundation to begin to understand the mechanism behind this highly specific 
phenotype. 
3.1 Introduction 
Toxoplasma gondii infection during pregnancy can result in devasting consequences for 
the developing fetus: neurological disorders, vision loss, and even death. Early detection (and 
treatment) of T. gondii infection is associated with decreased disease severity [254, 255], however, 
current diagnostics rely upon detecting the anti-Toxoplasma antibody response—a response that 
may take as long as several weeks to reach detectable levels.  
Previously, we not only found that primary placental trophoblasts restrict T. gondii 
infection, but that T. gondii infection also elicits a strong induction of immunomodulatory genes. 
Geneset Enrichment Analysis (GSEA) of differentially regulated genes during infection 
demonstrates a clear distinction in the responses of PHT cells contrasted with that of the JEG-3 
trophoblast cell line: the PHT cells respond to T. gondii infection with up-regulation of genes 
 82 
associated with immune response, immune system process, and defense response; while JEG-3 
cells induce genes related to wound-healing and tissue/organ morphogenesis (Appendix A, Figure 
24). To better understand the PHT cell’s response to T. gondii infection, we examined the induction 
of the chemoattractant CCL22. Furthermore, this CCL22 response is specific to T. gondii and not 
induced in response to the related parasite Neospora caninum. In this current work, we identify T. 
gondii dense granule protein GRA28 as both necessary and sufficient for CCL22 induction. 
Moreover, we attempt to understand the mechanism by which GRA28 mediates CCL22 induction 
and establish a foundation for future in vivo studies to examine the impact of CCL22 secretion on 
transplacental transmission of T. gondii and pregnancy maintenance. 
3.2 Results 
3.2.1  Toxoplasma gondii induces CCL22 in monocytes as well as primary trophoblasts 
T. gondii infection of PHT and monocyte/macrophage cells causes high induction of 
CCL22, a TH2 and TReg chemoattractant (Figures 13 & 16). As shown in Figure 16A & 16B, this 
induction in THP1 monocytes is shared among the three types of Toxoplasma common to Europe 
and North America (Types I, II, III). The degree of CCL22 induction increases both during the 
course of infection (Figure 16A & 16B) and in proportion with the multiplicity of infection 
(Figure 16C). As we previously saw with PHT cells, infection of THP1 monocytes with Neospora 
does not upregulate CCL22 production (Figure 16A).  
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Figure 16 T. gondii Infection Induces CCL22 in THP1 Monocytes 
(A, B) Timecourse of CCL22 induction and secretion during T. gondii infection of THP1 monocytes; MOI=1. (C) 
CCL22 induction by THP1 cells is dependent upon parasite burden, 26hpi. (D) Identification of host transcription 
factors uniquely expressed in PHT and THP1 cells but not HFF or JEG3 cells; analysis performed by Carolyn Coyne 
and Jon Boyle.  
 
As was noted in the previous chapter, CCL22 is induced in a cell-type specific manner and 
is not observed during infection of HFF or the JEG3 trophoblast cell line (Figure 13). We 
hypothesized this cell-type specificity could be related to expression of a unique subset of genes 
only found in primary trophoblasts and monocytes. Preliminary analysis of gene expression 
datasets publicly available on NCBI identified a set of host gene candidates that may help mediate 
CCL22 expression (Figure 16D), however transfection of the individual gene candidates into 
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JEG3 and HeLa CCL2 cells followed by infection (or later co-transfection with the parasite 
effector, GRA28) did not cause CCL22 induction (data not shown). However, it is possible that 
CCL22 induction requires the presence of multiple cell type-specific transcription factors or a host 
protein that was not identified in the initial screen of host gene candidates. To identify host cell 
binding partners of GRA28, I developed a construct to produce and secrete a mass quantity of 
recombinant GRA28 from E. coli (Appendix A, Figure 25). The rGRA28 has a c-terminal SUMO 
tag to permits purification via a nickel column. In future studies, fractions of cytosolic and nuclear 
proteins from RAW or THP1 cells will be incubated with pre-bound rGRA28 in order to pull-
down and identify protein interactors by mass spectrometry. Alternatively, studies utilizing 
proximity‐dependent biotin identification (BioID) could be used to identify these binding partners.  
3.2.2  CCL22 induction during Toxoplasma infection is dependent upon dense granule 
protein GRA28 
As was shown in the previous chapter, CCL22 induction during T. gondii infection is 
controlled by MYR1 expression (Figure 14F). MYR1 is a component of the Toxoplasma 
translocon for secretion of effector proteins beyond the parasitophorous vacuole into the host 
cytoplasm during intracellular infection [153, 154], and therefore unlikely to directly cause the 
induction of CCL22. In order to identify the true parasite effector, a list of candidate genes was 
generated by Elizabeth Rudzki and Jon Boyle based upon comparative genetics of T. gondii, 
Hammondia hammondi, and Neospora caninum (Figure 17A). Both T. gondii and H. hammondi 
are capable of inducing CCL22 in THP1 cells (S. Wong, E. Rudzki, & J.P. Boyle, personal 
communications), while N. caninum cannot. These three parasites are closely related and are 
highly syntenic: 99% of the T. gondii genome shares homology with H. hammondi [323], while 
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85% is shared in common with N. caninum [307]. Knock-out (KO) parasites were generated by 
Elizabeth Rudzki for each candidate parasite gene and tested for CCL22 induction in the THP-1 
monocyte cell line. By this method, GRA28 was identified as the necessary parasite effector 
(Rudzki & Boyle, personal communications). I validated the necessity of GRA28 for CCL22 
induction in primary trophoblasts by performing infections of second trimester placental villi with 
two independently generated GRA28-KO parasites (Figure 17B, 17C). 
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Figure 17 GRA28 Is Necessary & Sufficient for CCL22 Induction 
(A) Toxoplasma, Hammondia, and Neospora are closely related parasites, but only Toxoplasma and Hammondia are 
capable of inducing CCL22 in PHT cells and THP1 monocytes. (B, C) Infection of second trimester chorionic villi 
with two independently generated GRA28-KO parasites fail to induce CCL22. (D, E) Ectopic expression of 
GRA28Exon1 in HeLa cells. (F) Ectopic expression of GRA28 construct is sufficent for CCL22 induction by RAW 
macrophages. 
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3.2.3  GRA28 is sufficient for CCL22 induction 
After determining the necessity of GRA28 for CCL22 induction in human villous explants, 
I next examined whether ectopic expression of GRA28 alone is sufficient to induce CCL22. Based 
upon the GT1 (type I) genome on ToxoDB, I designed primers to create a plasmid for ectopic 
expression of GRA28 in mammalian cells. As various attempts to PCR-amplify the GRA28 
mRNA transcript failed, I used genomic DNA as my template. Interestingly, while the 
computationally-derived annotation on ToxoDB describes GRA28 as a 3-exon gene (2-exons on 
the ME49, type II, genome), compiled transcriptomic data suggests the possibility of alternative 
splicing and the presence of an early stop codon 11 nucleotides after the annotated end of the first 
exon. This alternative transcript annotation, consisting of the first exon and 11 additional 
nucleotides at the 3’ end, was used to synthesize the GRA28Exon1 construct with a V5/His tag at 
the c-terminus. Transfection of this construct in the RAW macrophage cell line was sufficient for 
CCL22 induction (Figure 17F). In accordance with live infection, this phenotype is specific to 
macrophages, as transfection into HeLa cells and the JEG-3 trophoblast cell line did not induce 
CCL22 (Appendix A, Figure 26). 
3.2.4  Nuclear localization may be important for GRA28 to mediate the induction of 
CCL22 
Ectopically expressed GRA28Exon1 localizes to the nucleus (Figure 18A), as has been 
previously shown with endogenously tagged GRA28 [151]. To investigate whether nuclear 
localization is required for CCL22 induction, I alanine-substituted the predicted nuclear 
localization signal (NLS) of GRA28 (Figures 18A, 19B). However, this did not completely 
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abrogate its nuclear localization (Figure 18B), and less stringent parameters for the NLS 
prediction algorithm revealed the possibility of several bipartite NLS. Thus, as an alternative 
method to prevent nuclear localization, I relocalized the GRA28 construct to other organelles in 
the host cell: the mitochondria and endoplasmic reticulum. GRA28Exon1 tagged with a 
mitochondrial localization signal did not localize to the nucleus (Figure 18D). However, this 
relocalization appeared to be toxic, as the plasmid was poorly expressed and by 48h the few cells 
expressing the construct showed signs of apoptosis. Meanwhile, the GRA28Exon1 construct tagged 
with an KDEL was successful in preventing nuclear localization (Figure 18E). However, the effect 
on CCL22 induction could not be assessed since both ER-GRA28Exon1 constructs and the control 
ER-mCherry plasmid caused CCL22 induction upon transfection into RAW cells (Figure 18F). 
Swapping GFP for mCherry did not resolve this non-specific induction. To identify necessary 
regions of GRA28 for CCL22 induction, two truncation mutants were made (Figures 18G, 19B). 
However, these mutants were still capable of inducing CCL22 and also localized to the nucleus 
(Figure 18G, 18H). Therefore, it still remains unclear what areas of GRA28 are required to 
mediate CCL22 induction. 
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Figure 18 Mutations of GRA28 Construct & Impact on Localization & CCL22 Induction in RAW 
Macrophages 
(A, B) Alanine-substitution of the predicted NLS increases the percentage of cytoplasmic GRA28-V5. (C) Mutation 
of the predicted NLS still permits CCL22 induction. (D, E, F) Relocalization mutants prevent nuclear accumulation 
of GRA28, but cannot be used to assess GRA28-mediated CCL22 induction. (G, H) Two truncation mutants, both 
still maintaining the N-terminus, are capable of inducing CCL22. 
3.2.5  Computation analysis predicts the presence of SLiMs that may mediate the functions 
of GRA28  
A recent study on Toxoplasma’s MYR translocon complex found that exportation of dense 
granule proteins is dependent upon their intrinsically disordered state, and the addition of a highly 
structured region prevents its translocation across the PV membrane [154]. As such, this likely 
explains the observation that most dense granule proteins are highly disordered and lack any 
predictable tertiary structure. Thus, instead of relying upon tertiary structure, it has been proposed 
that functions of dense granule proteins are driven by the presences of short linear motifs (SLiMs), 
3 to 11 contiguous amino acids in length [156, 158]. SLiMs can have roles in signal transduction, 
regulatory function, and protein-protein interactions [158–160].  
Computational analysis of GRA28 (type II, ME49 genome) for structure prediction found 
it to be highly intrinsically disordered with several putative mono- and bipartite nuclear 
localization signals (Figure 19A, 19C). Putative SLiMs were identified by analyzing the GRA28 
construct with the Eukaryote Linear Motif (ELM) online motif database. ELM analysis found 
GRA28 to be a highly disordered protein possessing many potentially interesting SLiMs that could 
be involved with GRA28 function, including: binding sites for PP2A, USP7, and TRAF2 (Figure 
19C; for full list of ELM hits see Appendix A, Figure 27). While the validity of these SLiMs 
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needs to be experimentally confirmed, especially as the small size of SLiM sequences 
consequently can result in a high number of false discoveries from computational prediction 
algorithms. Furthermore, it is also possible that some SLiM predictions may be true but be 
irrelevant for CCL22 induction; it is likely that GRA28 performs other functions in addition to 
stimulating CCL22 production. 
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Figure 19 Computational Analysis of GRA28 Construct 
(A) Prediction of NLS by NucPred [324]. (B) GRA28 mutant constructs. (C) Select hits from ELM analysis of GRA28 
construct. Full analysis is available in Appendix A, Figure 25. 
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3.2.6  Establishing an in vivo model to examine the effect of CCL22 induction on 
Toxoplasma transmission and maintenance of pregnancy 
In addition to defining GRA28’s mechanism of CCL22 induction, it is important to 
understand the role of CCL22 in congenital toxoplasmosis and pregnancy maintenance. Towards 
this goal, we have begun to establish a mouse model of congenital toxoplasmosis and parasite-
placental interactions. Ex vivo infection of murine placentas causes high secretion of CCL22 (E. 
Rudzki & J.P. Boyle, personal communications), and microscopic examination of infected tissue 
finds high levels of infection (Figure 20). In vivo infections of pregnant mice at embryonic day 8 
(E8) of pregnancy (performed by E. Rudzki & J.P. Boyle) also results in high parasite burden in 
the placenta by day E12 (Figure 21). Interestingly, infection is primarily localized to the decidua 
and junctional zone, with few parasites observed to invade the chorionic labyrinth. Matching 
histology with hematoxylin and eosin is located in Appendix A, Figure 28. In conjunction with 
the GRA28-KO parasite, future studies will utilize this in vivo model to better interrogate the roles 
of GRA28 and CCL22 on congenital transmission and pregnancy outcome. 
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Figure 20 Immunofluorescence Staining of Placenta Tissue Sections Infected Ex Vivo  
Sections of murine placentas infected ex vivo were stained for pan-cytokeratin and T. gondii. (A) Degree of 
fluorescence for T. gondii correlates with infectious dose: mock, 500,000 parasites, and 5 million parasites (type I, 
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RH). 4x images were stiched together using Photoshop to create an image of the full specimen. Scale bar represents 
500 µm. (B, C, & D) Selected images taken at 20x of the 5 million-infected placenta; scale bar represents 50 µm. 
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Figure 21 Immunofluorescence Staining of Placenta Tissue Sections from In Vivo Infection  
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Pregnant dams were infected at E8 of pregnancy with 1 million tachyzoites (ME49, type II) via a single intraperitoneal 
injection. Dams were euthanized on E12 and fetal tissues harvested. Sections of murine placentas infected in vivo 
were stained for pan-cytokeratin (CK, red) and T. gondii (Toxo, green). (A) A series of 10x images were stiched 
together using Photoshop to create a complete image of the full specimen; scale bar represents 500 µm. Tissue layers 
were identified and outlined by dotted white line: Dec, decidua; JZ, junctional zone; Lab, labrynth; CP, chorionic 
plate; YS, yolk sac villi. (B-E) Selected images were taken at 20x magnification; scale bar represents 50 µm. 
3.3 Discussion and Concluding Remarks 
Our present data illustrates the multifunctional role of placental trophoblasts: possessing a 
capacity to function like an immune cell in addition to their barrier function and epithelial 
lineage/origins. GSEA of differentially regulated genes in PHT cells following T. gondii infection 
(Appendix A, Figure 24) highlights the immunological barrier functionality of primary 
trophoblasts. Previously, we found T. gondii infection induces several immunomodulatory genes 
by primary trophoblasts, including the leukocyte chemoattractant CCL22. In the present study, we 
identify GRA28 as the parasite effector specifically driving CCL22 induction and begin to examine 
the mechanism by which it induces this phenotype. We found GRA28 to be both necessary and 
sufficient for CCL22 induction.  
Interestingly, GRA28 presents a cell type-specific ability to induce CCL22: whereas only 
primary trophoblasts and monocyte/MØ are capable of producing CCL22 in response to parasite 
infection or ectopic GRA28 expression. Furthermore, this phenotype is not recapitulated in any of 
the tested trophoblast cell lines. This phenomenon may be explained by several hypotheses. First, 
the chromatin accessibility of the CCL22 promoter is more relaxed or open in these specific cell 
types. In this scenario, GRA28 may act directly as a transcription factor and bind to the CCL22 
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promoter or it may indirectly promote CCL22 transcription by interaction with endogenous 
transcription factors. Second, GRA28 may interact with a host factor that is uniquely expressed in 
primary trophoblasts and monocytes/MØ. Our initial analysis of host transcription factors for cell-
specific CCL22 induction identified several candidates, yet transfection of these candidates into 
HeLa or JEG3 cells did not produce CCL22 induction. It is possible that (1) several of these 
transcription factors may be required together, (2) GRA28 interacts with a specific isoform not 
expressed by our plasmid constructs, or (3) GRA28 interacts with some other host factor all 
together. Interestingly, CCL22 was also induced when either the GRA28 construct or the control 
plasmid was relocalized to the endoplasmic reticulum. This correlation of CCL22 induction and 
increased protein localization at the endoplasmic reticulum suggests the CCL22 response may also 
be triggered by a cellular stress response pathway.  
In order to better understand the mechanism of GRA28’s function, I generated a construct 
for ectopic expression in mammalian cells. This construct localizes to the nucleus and is sufficient 
for CCL22 induction in RAW cells. Attempts to alter nuclear localization by mutating the 
predicted monopartite NLS or truncation found the c-terminus region (amino acids 169 to 484) to 
be dispensable for GRA28Exon1 trafficking to the nucleus. Repeated computational analysis for 
NLS prediction sites with reduced stringency revealed the presence of several putative bipartite 
NLS sites along the length of the protein. A similar phenomenon has been observed with another 
T. gondii dense granule protein, GRA16, where no single predicted NLS was found to be required 
for nuclear localization [147]. Thus, we can currently only hypothesize whether the nuclear 
localization of GRA28 is required for CCL22 induction. Future experiments could attempt to 
disrupt all predicted NLS to examine whether nuclear localization and CCL22 induction are 
abrogated. 
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I also computationally analyzed GRA28 for the presence of any SLiMs that could be 
mediating CCL22 induction. As many dense granule proteins are predicted to possess high 
intrinsic disorder, functional domains  of GRA proteins may consist of very short linear motifs 
rather than classical globular domains [158]. The flexibility of disordered regions promotes 
translocation by the MYR complex across the parasitophorous vacuole [154–156], and the short 
size is also evolutionarily advantageous as new SLiMs may arise (or disappear) with a single point 
mutation [161–163]. My analysis predicted the presence of several interesting SLiMs that may 
mediate CCL22 induction or other, novel functions of GRA28. However, as with all computational 
analyses, the validity of these predictions will need to be determined. It is not uncommon for SLiM 
interactions to be transient and possess weak binding affinities, both of which can cause difficulties 
in traditional pull-down assays for the identification of protein-protein interactions. As such, one 
alternative strategy for validating these SLiMs may be to tag GRA28 constructs with a biotin ligase 
in order to achieve a more complete network of GRA28 protein-protein interactions. 
In conclusion, our studies have identified the T. gondii dense granule protein, GRA28, as 
both necessary and sufficient to induce CCL22 in primary trophoblasts and monocytes/MØ. Due 
to the asymptomatic nature of T. gondii infection in the healthy adult, it is difficult to identify 
maternal infection in a timely manner to prevent vertical transmission. Current diagnostic methods 
rely upon detecting maternal seroconversion, however, the timing of maternal antibody response 
may not be detectable until weeks after infection. In our future studies, we hope to utilize this 
robust CCL22 phenotype as a biomarker for congenital infection and improved diagnostic for 
congenital toxoplasmosis. Towards that end, we have obtained clinical samples from women who 
seroconverted during pregnancy and are examining whether there are any correlations with 
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congenital toxoplasmosis diagnoses. Our future studies will also examine the impact of CCL22 on 
transplacental transmission of T. gondii and pregnancy maintenance. 
3.4 Materials and Methods 
3.4.1  Cell Culture 
All cell and tissue cultures were incubated at 37°C and 5% CO2 and all media were 
supplemented with 10% FBS. THP1 cells were grown in RPMI-1640 media (HyClone); HFF and 
RAW cells were grown in Dulbecco’s Minimum Essential Medium (DMEM; Lonza); HeLa CCL2 
cells were grown in Eagle’s Minimum Essential Medium (EMEM; Lonza) supplemented with 1x 
nonessential amino acids (HyClone) and 1mM sodium pyruvate (HyClone); and JEG-3 cells in 
Eagle’s Minimum Essential Medium (EMEM; Lonza).  
3.4.2  Mid-gestation placental explants 
Human placental tissue from less than 24 weeks gestation was obtained from the University 
of Pittsburgh Health Sciences Tissue Bank through an honest broker system after approval from 
the University of Pittsburgh Institutional Review Board and in accordance with the University of 
Pittsburgh anatomical tissue procurement guidelines. Chorionic villi were dissected and cultured 
in DMEM/F12 (1:1) supplemented with 10% FBS, penicillin/streptomycin, and amphotericin B. 
For T. gondii infections, isolated tissue was infected immediately following isolation with 1x106 
parasites for ~24hrs.  
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3.4.3  Parasites 
Type I (RH) T. gondii tachyzoites were used for this study. GRA28-KO parasites were 
generated by E. Rudzki. All parasites were maintained by continual passage in human foreskin 
fibroblast (HFF) cultures incubated at 37°C and 5% CO2 in DMEM supplemented with 10% FBS, 
50 µg/mL penicillin/streptomycin, and 2mM glutamine. For infections, infected monolayers were 
scraped and syringe-lysed to release the tachyzoites. These parasites were then pelleted at 800 x g 
for 10 minutes, resuspended in fresh media, filtered through a 5 µm filter, and counted to determine 
the appropriate dilution for infection. Mock inoculum was produced by filtering out the tachyzoites 
with a 0.2 µm filter.  
In vivo infection of pregnant Swiss-Webber mouse was performed on day E8 of pregnancy, 
where day E0 was defined as the day a vaginal plug was observed after co-housing with a male. 
Infection consisted of a single intraperitoneal injection of 1 million tachyzoites (type II, ME49). 
The dam was euthanized on day E12, and fetal tissues were collected for histology. 
3.4.4  Plasmid construction 
The first predicted exon of GRA28 (excluding the 18 nucleotides upstream of the predicted 
signal peptide) was amplified from genomic DNA and TOPO cloned into a pcDNA3.1 vector with 
a c-terminus V5/His tag (Invitrogen). Primer sequences were as follows: 
GCCACCATGCAGACAAATCCTGATCTCGATAATCTATG (forward, 5’-3’); 
GTCCTCCCAATTGTCCGGTCTTACTCCGGTCTTACCC (reverse, 5’-3’). To alanine-
substitute the predicted NLS, the following primers were used: 
CGCAAGTAAGGCAGCTGCAGCAGCTGCAGGTGGCGAAGGTG (forward, 5’-3’); 
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CTTCGCCACCTGCAGCTGCTGCAGCTGCCTTACTTGCGGC (reverse, 5’-3’). To create 
truncations at the c-terminus, the following reverse primers (5’-3’) were used: 
AGCTGATGTTGTACCCGGAGGCCCCG (truncation A) and 
CATACTTGGAGGTCGCTGCTCAAGAGCTTTTC (truncation B).  
3.4.5  Transfections 
Transfection of JEG-3 and RAW cells was performed using Lipofectamine 3000 (ratio of 
2µg DNA to 2µL of P3000 reagent and 4µL of Lipofectamine 3000 reagent. Transfection of all 
other cells was performed with XtremeGene HP (ratio of 0.5µg of DNA to 1.5µL of transfection 
reagent). 
3.4.6  CCL22 ELISA 
CCL22 ELISAs were performed with the human or mouse CCL22/MDC DuoSet ELISA 
(R&D Systems) as per the manufacturer’s instructions. 
3.4.7  Microscopy 
Cell monolayers were fixed in 4% paraformaldehyde and permeabilized with 0.1% Triton 
X-100 in 1x PBS. Primary antibodies were incubated for 1h at room temperature, followed by 
washing, then secondary antibodies conjugated to Alexa Fluor (Invitrogen) fluorophores for 30min 
at room temperature. Following washing, cells/explants were mounted with DAPI-Vectashield 
(Vector Laboratories) and imaging performed on an Olympus IX83 inverted microscope. In some 
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cases, imaged were adjusted for brightness and contrast using Photoshop or Fiji/Image J. Image J 
was used for image analyses. Reagents and antibodies used for immunostaining studies include 
Alexa Fluor 594 or 633 conjugated phalloidin (Invitrogen), anti-V5 (Invitrogen), MTCO (Abcam).  
3.4.8  Computational Analysis 
Prediction of protein structure and short linear motifs was performed using the Eukaryotic 
Linear Motif resource (ELM), located at http://elm.eu.org. Nuclear localization signal prediction 
was performed with NucPred, available at https://nucpred.bioinfo.se/cgi-bin/single.cgi. N-terminal 
signal peptide cleavage site of GRA28 was identified using SignalP 4.1 Server 
(http://www.cbs.dtu.dk/services/SignalP/).  
3.4.9  Western Blotting 
Cells were lysed in cold RIPA buffer (Millipore) supplemented with 1x proteinase inhibitor 
cocktail (Thermo Scientific), and lysate was cleared by centrifugation at 13000 xg for 15min at 
4°C. Protein concentrations were determined by BCA assay (Thermo Scientific), and 30µg 
samples were separated on a 4-20% Tris-HCL gel (Bio-Rad). Proteins were transferred to PVDF 
membranes and blocked with 10% nonfat dried milk in PBS before antibody probing. Blots were 
developed for detection with chemiluminescence. 
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3.4.10  RT-qPCR 
RNA was isolated from cultures using the GenElute™ Mammalian Total RNA Miniprep 
Kit (Sigma) and the associated DNase digestion set (Sigma). cDNA  was generated using the 
iScript cDNA synthesis kit (Bio-Rad), followed by qPCR using a StepOnePlus Real-Time PCR 
System (ThermoFisher). The ∆CT method was used to determine gene expression and normalized 
to the human actin CT of each sample. Primer sequences were as follows: Human Actin—
ACTGGGACGACATGGAGAAAAA (Forward, 5’-3’); GCCACACGCAGCTC (Reverse, 5’-
3’). Human CCL22—GTGGTGTTGCTAACCTTC (Forward, 5’-3’); 
GGCTCAGCTTATTGAGAATC (Reverse, 5’-3’). 
3.4.11  Immunohistochemistry 
Tissue sections were deparaffinized with xylene and rehydrated with decreasing 
concentrations of ethanol (100%, 95%, 80%), and washed with ddH20. Antigen retrieval was 
performed with slides submerged in 10mM citrate buffer (pH 6.0) and heated in a standard 
microwave for 3 5-min intervals. Slides were cooled to room temperature and incubated with 
rodent block for 30mins (from the Mouse on Mouse Polymer IHC Kit from Abcam). Sections were 
incubated with anti-Toxoplasma (LS Bio, 1:25) and anti-pan cytokeratin (Invitrogen, 1:50), diluted 
in 1% BSA in PBS, and incubated overnight in a humidified chamber at 4oC. The next day, slides 
were rinsed thrice in TBS-T (Tris-buffered saline, 0.1% Tween-20) and incubated with secondary 
antibodies conjugated to Alexa Fluor (Invitrogen) fluorophores for 30min at room temperature. 
Following washing, sections were mounted with DAPI-Vectashield (Vector Laboratories) and 
imaging performed on an Olympus IX83 inverted microscope using a UC90 color CCD camera 
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(Olympus). In some cases, imaged were adjusted for brightness and contrast using Photoshop or 
Fiji/Image J. H&E staining was performed by the Rangos Histology Core. 
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Appendix A Supplementary Figures 
 
Figure 22 Markers of Autophagy & Lysosomal Degradation Do Not Associate with T. gondii 
Immunofluorescence microscopy of PHT cells infected with T. gondii (YFP-RH, multiplicity of infection of 4) 
(green). (A) LC3B staining is shown in yellow, actin is in red, and DAPI-stained nuclei are shown in blue at 8 h 
postinfection. (B) Lysosome-associated membrane protein 2 (LAMP2) is shown in red and DAPI is shown in blue at 
24 h postinfection. 
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Figure 23 CCL22 Is Not Anti-Parasitic 
PHT cells were superinfected with 2.16 × 105 YFP-RH parasites for 24 h and stained with cytokeratin 19, phalloidin, 
and DAPI in order to distinguish cell type and boundary. Degree of infection was determined by parasite area as 
percentage of host cell, from images taken of two technical replicates from one PHT preparation. (A) PHT cultures 
were treated with a neutralizing antibody to CCL22 at the time of infection. (B) Cultures were pretreated with 1 ng/ml 
of rCCL22 for 24 h prior to infection.  
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Figure 24 Geneset Enrichment Analysis (GSEA) of Differentially Regulated Genes Following Infection of 
JEG-3 or PHT cells 
GSEA was performed on pre-ranked lists of differentially regulated genes (fold-change +/- 1.5 
log2; p-adj value <0.01) in either JEG-3 cells or PHT cells. Genesets used for analysis include 
“Hallmark,” “Immunological Signatures,” and “Gene Ontology.” However, only comparison to 
the “Gene Ontology” geneset resulted in the identification of genesets significantly enriched 
(FDR<25%; nominal pvalue <1%). 
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Figure 25 E. coli-Expressed Recombinant GRA28 
Inducible induction of GRA28 construct by E. coli by the addition of 1mM Isopropylthio-β-galactoside (IPTG) to 
bacterial broth. This recombinant GRA28 is c-terminally tagged with SUMO instead of V5/His. 
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Figure 26 Ectopic Expression of GRA28 Construct Does Not Induce CCL22 in HeLa or JEG-3 Cells 
EGFP or GRA28 construct was transfected in HeLa and JEG-3. CCL22 transcripts were measured 
using qPCR and normalized to EGFP samples. 
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Figure 27 Full ELM Analysis of GRA28 Construct 
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Figure 28 H&E Staining of Placenta Tissue Sections Infected In Vivo  
A series of 10x images were stiched together using Photoshop to create a complete image of the full specimen. Tissue 
layers were identified and outlined by solid black line: Dec, decidua; JZ, junctional zone; Lab, labrynth; CP, chorionic 
plate; YS, yolk sac villi. (B-D) Selected images were taken at 20x magnification and roughly correspond to similar 
areas on the section that was stained for immunoflourescence. 
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Appendix B Copyright Permissions 
Subchapter 1.1 and Chapter 2 were previously published and are presented herein in a 
modified form either with permission of the copyright holder (Science Immunology) or under the 
Creative Commons CC BY license (mBio): 
 
Ander SE, Diamond MS, Coyne CB (2019) Immune responses at the maternal-fetal 
interface. Sci Immunol 4:eaat6114. https://doi.org/10.1126/sciimmunol.aat6114. Reprinted 
with permission from AAAS. 
 
Ander SE, Rudzki EN, Arora N, Sadovsky Y, Coyne CB, Boyle JP (2018) Human Placental 
Syncytiotrophoblasts Restrict Toxoplasma gondii Attachment and Replication and 
Respond to Infection by Producing Immunomodulatory Chemokines. MBio 9, e01678-17. 
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